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HIV/AIDS remains one of the most pressing challenges facing South African society. South 
Africa has the highest number of people living with HIV as well as the highest number of 
people on HIV treatment globally, yet only 37% of persons eligible for treatment have access 
to treatment. 
 
The advent of HAART ushered in a new era in the treatment of HIV infection.  HIV infection 
was no longer a life threatening terminal illness, HIV/AIDS became a chronic manageable 
disease.  The full clinical benefit of HAART can only be achieved with near perfect 
adherence i.e. > 95%. This means taking the medication exactly as prescribed; on time, no 
missed doses, every day, lifelong. No other chronic medication requires such stringent 
adherence rates for optimal therapeutic benefit, which may mean the choice between life and 
death. Achieving near perfect adherence poses a serious challenge to health service providers 
and persons on treatment as typical adherence rates for medication prescribed over long 
periods are in the 50 – 75 % range.  Persons on HAART live with the additional burden of 
drug resistance and limited treatment options if near perfect adherence rates are not achieved. 
 
The purpose of this qualitative study was to explore the factors that influence adherence to 
HAART. These factors may be related to the person, the health care team and system, the 
treatment regimen, the social and economic environment or to the effects of HIV disease.  
Factors may either negatively or positively influence a person’s ability to adhere optimally to 
their prescribed treatment.  
 
A small sample of thirteen participants were purposefully selected for this study.  Data was 
collected using in-depth interviews which were tape recorded and transcribed for thematic 
analysis.  The value of this study is that it may assist health care providers, persons on 
treatment and the health care system to better comprehend the challenges of lifelong optimal 
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Chapter 1:  Introductory Chapter 
 
1.1  Background and Outline of Research Problem 
South Africa has the largest population of people living with HIV/AIDS, the largest number 
of people on antiretroviral therapy (ART) and the largest public health ART programme in 
the world (UNGASS RSA, 2010).  In 2008 approximately 5.7 million South Africans were 
living with HIV or 18 % of the adult population were HIV positive. In the same year an 
estimated 250 000 lives were lost due to AIDS related diseases (UNAIDS, 2010b).   
 
Estimates of the HIV prevalence rates are obtained from the Antenatal HIV Sero-prevalence 
Survey which is conducted annually among pregnant women aged 15-49 years.  These results 
are also used to estimate the HIV prevalence in the general population.  According to the 
2008 Antenatal survey report, the overall national HIV prevalence among antenatal women 
aged 15 – 49 was 29.3%.  In 2006 and 2007 the HIV prevalence was 29% and 29.4% 
respectively.  This indicates that the pandemic appears to have stabilized over the last few 
years, albeit at alarmingly high levels (UNGASS  RSA, 2010). 
 
The HIV/AIDS pandemic not only causes death and suffering on an individual and 
community level, but also has a substantial impact on a countries overall social and economic 
progress.  Average life expectancy in South Africa is around 54 years, hospitals are 
struggling to cope with the number of HIV related sick persons they have to care for, children 
have lost parents, schools have fewer educators (2006 estimate of teachers living with HIV 
was 21%), not to mention the impact of the HIV pandemic on health care workers.  People 
infected with HIV are more susceptible to TB infection thus fuelling the already alarming TB 
epidemic.   
 
The year 2008 signalled the end of President Thabo Mbeki’s era of HIV/AIDS denialism, and 
heralded in what appears to be the emergence of a comprehensive and determined response to 
the HIV/AIDS epidemic in South Africa. After years of HIV/AIDS denialism during the 
Mbeki era and mixed messages about the efficacy of antiretroviral agents there is evidence of 
committed leadership and political will to confront the challenges that HIV/AIDS poses to 
South Africa and its people. 2010 saw South Africa launch one of the most ambitious and 
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quickest scale-ups of a HIV/AIDS response ever.  The South African government, under the 
leadership of President Jacob Zuma,  approved a plan to test one third of the population for 
HIV by the end of 2011, to halve the rate of new infections and to provide antiretroviral 
therapy to at least 80% of persons in need of treatment (UNAIDS, 2010b). 
 
Antiretroviral therapy (ART) or highly active antiretroviral therapy (HAART) is the only 
known treatment that is consistently effective in delaying the progression from HIV to AIDS.  
HIV anti-retroviral drug treatment has transformed HIV/AIDS from a life-threatening disease 
to a manageable chronic disease and this means that HIV positive people can maintain their 
health and lead relatively normal lives.  Persons who adhere to their medication are also less 
infectious and less susceptible to opportunistic infections and cancers, thus supporting the 
goal of reducing the rate of new infections and lessening the burden of disease on the health 
system. 
 
The 2010 UNGASS Country Progress Report states that the South African public ART 
programme had approximately 919,923 people on treatment by the end of November 2009. 
An additional estimated 51.633 people were accessing ART either using private health care 
or the non-governmental (NGO) sector. 
 
Critical to treatment success is adhering stringently to a potent combination of highly active 
antiretroviral drugs that requires near perfect adherence, for life (Orrell, 2004).  The term 
compliance and adherence is often synonymously used to refer to taking medication exactly 
as prescribed.  Adherence is however the preferred term as compliance implies that some 
prompting is necessary to ensure that the medication is taken whereas adherence is a 
voluntary action by the person in need of treatment (Orrell, 2004).  Horne (2006) asserts that 
the use of the term compliance has been criticised as it was thought to convey a negative 
image of the relationship between the person in need of treatment and the prescriber. The 
prescriber appears to be issuing instructions and the person in need of treatment is expected 
to follow those instructions. Noncompliance therefore implied incompetence or self-
sabotaging behaviour towards medical treatment (Horne, 2006).  Adherence according to 
Horne (2006) was introduced as a way to recognise the person’s right to choose treatment and 
to remove the concept of blame.  A range of factors may influence a person’s ability to 
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adhere stringently to their  prescribed  medication  and greater  insight into  these factors may 
enable the  necessary interventions to ensure near perfect lifelong adherence. 
 
1.2  Rationale for the Study 
KwaZulu-Natal province, the epicentre of the South African HIV epidemic has the highest 
prevalence and incidence rates of HIV in the country.  The majority of HIV infected patients 
will eventually need antiretroviral therapy, and near perfect (>95%), sustained adherence to 
HIV treatment is critical if a healthy long life is the expected outcome. 
 
Sub-optimal adherence to HIV medication has potentially severe health outcomes which may 
reduce treatment efficacy, cause drug resistance and increase morbidity and mortality as the 
individual becomes more susceptible to opportunistic infections such as cryptococcal 
pneumonia and tuberculosis. 
 
HIV and TB in South Africa are referred to as the tale of two epidemics or the terrible twins 
that are silent killers  (Laloo, 2007).  What is equally disturbing is that the HIV epidemic is 
fuelled by the TB epidemic and the TB epidemic is fuelled by the HIV epidemic.  HIV 
negative persons in South Africa have a life time risk of 10% of developing TB.  HIV 
positive persons have a life time risk of 10% per annum of developing TB (Laloo, 2007). TB 
is the leading cause of death in South Africa and the main cause of death for those living with 
HIV/AIDS (Stanwix, 2010). Taking into consideration the high prevalence rates of HIV in 
South Africa reiterates the importance of accessing early treatment combined with optimal 
adherence to prevent susceptibility to opportunistic infections. 
 
South Africa, during the Mbeki presidency was ashamedly at the receiving end of mixed 
messages and incorrect information concerning the existence of HIV and the value of ART as 
life saving medication.  People may therefore question the efficacy of ART, or misunderstand 
issues of toxicity of ART, which may lead to either sub-optimal adherence or not accessing 
life-saving medication. 
 
Antiretroviral treatment regimens may be complex and side effects severe, therefore without 
expertise and resources to evaluate and support adherence, antiretroviral therapy can be 
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ineffective, wasteful and dangerous. This once again reiterates the importance of 
understanding factors that influence adherence to inform strategies to promote adherence. 
 
Mills, Nachega, Bangsberg, Singh,  Rachlis, Wu, Wilson, Buchan,  Gill and Cooper  (2006) 
in their systematic review of developed and developing nation patient-reported barriers and 
facilitators to HAART adherence found that research to determine patient-important barriers 
and facilitators for adherence in developing world settings is lacking.  Studies on factors 
affecting adherence have mostly been associated with defined populations in specific settings 
in developed nations. This limitation means that the findings may not be generalized to 
dissimilar populations thus suggesting the ongoing need for studies on defined populations to 
inform strategies to improve adherence. 
 
Research on the topic of adherence is emerging from developing countries worldwide and in 
Africa, particularly Southern Africa  (Amberbir,  Woldemichael,  Getachew,  Girma, &  
Deribe, 2008;  Aspeling & van Wyk, 2008; Dahab, Charalambous,  Hamilton, Fielding,  
Kielman, Churchyard & Grant, 2008; Frank & Duncan, 2009; Gilbert & Walker, 2009; 
Nachega, Stein, Hlatshwayo, Mothopeng, Chaisson & Karstaedt, 2004 and Naidoo, 2009 are 
examples of studies). What is apparent from these studies and what justifies this study is 
recognising the value of the subjective experiences of HIV positive people in need of 
treatment with regard to the factors that influence their ability to take their medication as 
prescribed. 
 
Information so gleaned enables a broader and more in-depth understanding of specific issues 
that may affect a specific community or population of people and the individual in that 
community.  Such  information may also shed light on the fact that a one fit for all approach 
to adherence counselling is not necessarily in the best interests of persons in need of 
treatment.  It is also important to impress upon health care workers the value of the subjective 
experiences of persons on treatment and to promote a case by case approach to tailoring 
interventions to meet the needs of the individual and the community. More emphasis on the 
individual’s unique subjective experiences may also enable greater insight into strategies that 
enhance adherence.  The information gathered may assist health-care workers to encourage 
and engage in open discussion with persons on ART to promote HIV medication adherence 
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or may inform strategies to improve adherence (Mills, Bangsberg, Nachega, et al., 2006).  
This type of open relationship is both empowering and person-centred and may lead to a type 
of partnership in health care between health care providers, health care receivers and the 
systems that influence health care. 
 
1.3  Research Problem and Objectives 
The main objective of this study was to explore the factors that influence adherence to HIV 
antiretroviral therapy. Therefore the specific objectives were to gather in-depth information 
about the following factors that influence HIV medication adherence: 
 
• Social and economic factors  
• Health care provider and system related factors 
• Condition related factors 
• Therapy related factors 
• Person related factors  
 
The researcher prefers to use the word person rather than patient because the word patient 
tends to imply illness as well as a dependent or subservient position.  The word person or 
people sends a message of empowerment, which means responsibility for one’s own health 
and being respected as equals in decisions about health care. 
 
1.4  Key Questions  
 
• What specific influences might social and economic factors have on adherence to 
antiretroviral therapy? 
• What roles do health care providers and the health system play in facilitating 
adherence to ART? 
• Does the medical condition of the HIV positive person influence antiretroviral 
medication adherence? 
• Are there specific therapy related factors that might influence adherence? 




1.5  Theoretical Framework 
This study was guided by three theoretical approaches; the ecosystems perspective, the bio-
psychosocial model of health and the information-motivation-behavioural theory of health 
promotion.  Adherence behaviour is described as a multidimensional phenomena influenced 
by the interaction between five sets of factors or dimensions namely; health care system 
factors, social and economic factors, factors related to the condition, therapy factors and 
person related factors (WHO, 2003). The ecosystems perspective provides a framework that 
focuses on the interplay between the person and his or her environment.  In order to view a 
person holistically, it is important to understand and appreciate the environmental context 
within which this person exists. This context takes into cognisance the fact that the person 
exists within families; families exist within communities; individuals, families and 
communities exist within a particular political, economic and cultural environment and this 
environment impacts upon the actions, beliefs and choices available to the person (Berger, 
McBreen & Rifkin, 1996; Rengasamy, 2010).  In other words the ecosystems perspective 
focuses on multiple levels of phenomena simultaneously and provides insight into how the 
interaction between the different levels affects or impacts on behaviour. This perspective 
therefore enables a more holistic view of human behaviour as such an approach attempts to 
understand an event or behaviour in its larger context (Berger et al., 1996).  
 
The bio-psychosocial model of health and illness as opposed to the biomedical model of 
health and illness is based on a systems approach and provides a holistic view of health and 
illness.   This approach posits that health care workers attend to the biological, psychological 
and social dimensions of health, illness or health behaviour as these dimensions all interact in 
significant ways to influence human functioning, reminding us that nothing ever exists in 
isolation. This model encourages the health care worker to assess the influence of multiple 
systems on health behaviour and illness.  This process illuminates the context in which the 
health behaviour or disease occurs and enables the health care worker to gain a broader 
understanding of disease and other health related issues or behaviours. Both the ecosystems 
perspective and the bio-psychosocial model provide a holistic view of health, illness and 
health behaviour and enables greater insight into the complexities of human nature and 
behaviour and the significance and influence of context on human situations. Theories in 
health promotion such as the information-motivation-behavioural change model, has been 
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articulated as a general model for health behaviour change.  According to this model if a HIV 
positive person is well informed about their antiretroviral therapy, is motivated to act, and has 
the necessary behavioural skills to act effectively, then he or she is likely to adhere to their 
medication regimen and to reap the profound health benefits of such behaviour.  Conversely, 
if a person is poorly informed about their antiretroviral therapy, lacks motivation and has not 
acquired the necessary skills for medication adherence, then this person is more likely to be 
non-adherent, and will therefore not achieve the health benefits of their treatment (Fisher & 
Fisher in DiClemente, Crosby & Kegler, 2002). Theories may assist in the design of 
behaviour change interventions to promote adherence, but it must be emphasized that 
ensuring long-term treatment adherence presents considerable challenges to healthcare 
initiatives.   
 
HIV and TB, may be particularly challenging because both are chronic, infectious, involve 
complex treatment regimens and require near perfect adherence rates for many months for 
TB and lifelong in the case of HIV infection (Munro, Lewin, Swart & Volmink, 2007; Orrell, 
2004; Ware, Wyatt & Bangsberg, 2006).   
 
1.6  Presentation of Contents 
 
Chapter 1:  Introductory Chapter 
The introductory chapter includes a brief description of the context of the HIV/AIDS 
epidemic in South Africa, the prevalence of the disease, the impact of the epidemic on 
communities as well as the era of HIV/AIDS denialism and the consequences of that period.  
The rationale for this study is explored to enable the reader to see value of this research.   The 
research objectives and research questions are clearly documented as well as the three 
theoretical approaches, which serves to guide this study. 
 
Chapter 2:  Literature Review 
A detailed account of the literature to broaden understanding about HIV/AIDS and the factors 
that influence adherence to antiretroviral medication is presented in Chapter two. The 
literature review starts off with the global update of the HIV/AIDS epidemic and then goes 
into detail about the South African epidemic including the factors that may fuel the South 
8 
 
African epidemic.  The latest reports on the HIV/AIDS epidemic globally were used to give 
updated information about the epidemic.  The UNAIDS (2010a) global report is significant 
because for the first time in the history of the HIV pandemic there is evidence that new 
infections globally and in South Africa have decreased.  HIV/AIDS policy and the challenges 
facing the HIV/AIDS response are presented.  This chapter also explains the natural history 
of HIV/AIDS infection without medication as well as prognosis and staging of this disease.  
The new ART guidelines are explored as well as the goals of ART.  Adherence and the 
importance of near perfect adherence are discussed in great detail.  Lastly the various factors 
that influence adherence are discussed in detail. 
 
Chapter 3:  Research Methodology 
The methodology chapter explains the reasons for the qualitative method as the method of 
choice for this study.  The sampling technique, sample size and sampling criteria as well as 
the justification for the choices are documented in this chapter.  The data collection method 
and data analysis are justified and explained as well as the important ethical considerations 
that concern this study. The reliability and validity as well as the limitations of the study are 
also explained in this chapter. 
 
Chapter 4:  Results 
The entire process of data capturing from the transcripts is explained in this chapter. The data 
collected for this research study was carefully analysed using colour coding and presented 
under categories and subcategories.  Tables were used when necessary to ensure that all data 
was accounted for and to ensure that the researcher took every aspect of the findings into 
account when analyzing the data.  The results were then discussed according to the categories 
or themes that emerged taking into consideration the literature available on the findings.  
 
Chapter 5:  Major conclusions and Recommendations 
The findings were consolidated in the major conclusions in this final chapter.  The conclusion 
also discusses the value of the research study to the general knowledge on HIV adherence 
and identifies possible areas for ongoing research.  The researcher also takes the opportunity 




Chapter 2:  Literature Review 
 
2.1  Global Update of the HIV/AIDS Pandemic 
“The number of people living with HIV worldwide continued to grow in 2008, reaching an 
estimated 33.4 million (31.1 million - 35.8 million). The total number of people living with 
the virus in 2008 was more than 20% higher than the number in 2000, and the prevalence was 
roughly threefold higher than in 1990” (UNAIDS & WHO, 2009). This Joint United Nations 
Programme Report on the HIV/AIDS epidemic for 2009 summarises the latest data on the 
epidemiology of HIV worldwide (UNAIDS & WHO, 2009).  The epidemic appears to have 
stabilized in most regions of the world except in Eastern Europe and parts of Asia, where 
prevalence rates have increased.   
 
Sub-Saharan Africa remains unequivocally the worst affected region in the world accounting 
for 71% of all new infections in the year 2008 (UNAIDS & WHO, 2009). Sub-Saharan 
Africa is home to over two thirds of all people living with HIV and nearly three quarters of 
AIDS related deaths worldwide  (UNGASS RSA, 2010).  In most countries in Southern 
Africa, South Africa included, HIV prevalence has stabilized at alarmingly high levels. Some 
areas like rural Angola still indicate increased incidence rates (UNAIDS & WHO, 2009). 
 
2.2  The South African Epidemic 
South Africa ranks as one of the most severely affected countries in the world with regards to 
the HIV/AIDS epidemic and is home to the largest number of people infected with the human 
immunodeficiency virus in the world.  In 2009 the estimated number of people living with 
HIV in South Africa was approximately 5.7 million indicating a prevalence rate of 18.1% 
(UNAIDS & WHO, 2009).  Using a different mathematical model, the 20th antenatal survey 
estimates for 2009 are 5.63 million living with HIV and a prevalence of 17.8% (Department 
of Health, 2010).  More that 3 million of these were women aged 15 and over, and 280,000 
were children between the ages of 0-14 years.  For this reason, South Africa sadly hosts the 
world’s largest population of people living with HIV (UNGASS RSA, 2010).  The 20th 
antenatal sero-prevalence survey in South Africa provided evidence that the national HIV 
prevalence has stabilized around 29%.  The highest prevalence was recorded in KwaZulu-
Natal with an increase from 38.7% in 2008 to 39.5% in 2009.  What is disturbing according 
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to this report is the number of districts in KwaZulu-Natal recording prevalence above 40%.  
This clearly indicates the need for more research into high risk and low risk areas to 
determine what the main drivers of HIV infection rates are in high prevalence areas and what 
keeps prevalence levels at lower levels in low risk areas (Department of Health  RSA, 2010). 
 
Extrapolation of HIV infection to the general population indicates that prevalence rates 
decreased marginally from 17.9% in 2008 to 17.8% in 2009.  Provincial HIV prevalence rates 
reveals that KwaZulu-Natal has the highest prevalence at 25% in 2009 (25.1% in 2008) and 
the Western Cape the lowest prevalence rate, at 6.2% in 2009 and 2008 (Department of 
Health RSA, 2010). 
 
South Africa is experiencing a maturing generalized HIV epidemic defined as being hyper-
endemic because more than 15 % of the population aged between 15-49 years old are living 
with HIV (high prevalence rate), and because of the modes and drivers of HIV transmission 
(Shisana, Rehle, Simbayi, Zuma, Joose, Pillay-van-Wyk, Mbelle, Van Zyl, Parker, Zungu, 
Pezi & the SABSSM III Implementation Team, 2009; UNGASS  RSA, 2010). 
 
Heterosexual sex is the predominant mode of HIV transmission followed by mother-to-child 
transmission as well as other modes of transmission, for example, men who have sex with 
men.  Injecting drug use is not common in South Africa at this point in time, blood product 
safety conforms to international standards, and transfusion associated infections are 
extremely rare (Shisana et al., 2009). Drivers of the epidemic include socio-structural drivers 
such as high population mobility, wealth inequalities, culture and gender inequality, human 
rights violations; contributing drivers, such as, male attitudes and behaviours, 
intergenerational sex,  gender and sexual violence, stigma, lack of openness and untreated 
STIs; and lastly, the key drivers, which are,  multiple and concurrent sex partnerships by men 
and women with low condom use in the context of low levels of male circumcision 
(AIDS2031, 2010).  The authors of AIDS2031 (2010) conclude that a wide range of factors 
appear to fuel HIV epidemics in hyper-endemic countries like South Africa and other 
Southern African countries. The relative contribution of these factors in fueling the HIV 
epidemic appear to vary from place to place making it difficult to quantify their impact on the 
HIV epidemic. However, the authors assert that there is evidence to suggest that two factors 
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converge in the hyper-endemic regions with great potency together with other HIV risk 
factors (STIs, sharing needles/syringes, blood exposure, needle stick injuries). These two 
factors, and key drivers, of the Southern African epidemic are a generalized lack of male 
circumcision and multiple concurrent partnerships.  
 
Male circumcision reduces the risk of heterosexually acquired HIV infection in men by 60% 
and should be considered an efficacious intervention for HIV prevention in countries with 
heterosexual epidemics, high HIV prevalence and low male circumcision prevalence (WHO: 
male circumcision for HIV prevention, undated).   Reducing multiple concurrent sexual 
partnerships must be seen as a priority for reducing new infections (AIDS2031, 2010). 
 
At a UNAIDS (Joint United Nations Programme on HIV/AIDS) meeting in Zambia in 
December 2006, Peter Piot, former Executive Director of UNAIDS emphasized the need to 
address the drivers of the epidemic: “It is patently clear that we need to make real headway 
against fundamental drivers of this epidemic, especially gender inequality, stigma and 
discrimination, deprivation and the failure to protect and realise human rights.  This challenge 
is perhaps the greatest of all those facing the AIDS response. And there can never be a 
technological fix for these social issues.  We need positive social change – and all of us in the 
AIDS effort must be willing to back this. I am increasingly convinced that just expanding 
programmes, doing more, even much more, is not going to stop this epidemic.  To reach 
universal access to HIV prevention, treatment, care and support we need to pay attention to 
the drivers” (UNAIDS. Drivers of the epidemic, undated).  All the United Nations member 
states (South Africa included) committed to attaining universal access to HIV prevention, 
care and treatment and stressed that gender inequality, discrimination and the marginalization 
of vulnerable groups constitute major detractors to universal access (UNAIDS. Drivers of the 
epidemic, undated). 
 
The UNAIDS (2010a) global report reveals that new infections globally and in South Africa 
have decreased considerably over the past decade.  Increased condom use, abstinence and 
improved HIV awareness have contributed to a fall in infections; however the report cautions 
that Sub Saharan Africa, the epicenter of the epidemic, continues to be disproportionately 
affected, bearing approximately 70% of the global burden of HIV/AIDS. Mark Heywood, 
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deputy chairperson of South Africa’s National AIDS Council said there were still more 
challenges than successes.  “When we have less than 50% of people who need treatment on 
treatment, when we’re still failing on prevention, then I don’t think there’s anything to crow 
about at this stage.  We can be optimistic, but the hard work still lies ahead” (UN: AIDS 
epidemic slowing, 24 Nov 2010). 
 
The cost of apartheid South Africa’s non-action, plus failure to act effectively during the 
Mandela presidency, compounded by denial of HIV/AIDS during the Mbeki governance are 
at the root of the enormity of the HIV/AIDS epidemic that South Africa faces today.  Mark 
Heywood stated that the Zuma administration seems to have the political will to respond 
effectively but the challenge has grown so large that it is difficult to manage and government 
simply does not have enough resources to tackle this disease (cited in Aziz, 2010). 
 
Heywood went on to explain that the health care system in South Africa is more unequal now 
than it was during the apartheid era: ZAR80 million is spent on private health care for 16 % 
of the population and the same amount of spending is available for the rest of the population.  
The public health system also does not have the human resources to deal with the health 
burdens facing the majority of the people of South Africa. 
 
To add to this bleak scenario was the antiretroviral drug pricing debacle which saw South 
Africa fixed into paying almost double the cost for lifesaving ARVs.  Thankfully, South 
Africa’s newly announced tender for ARVs has now halved the price government would pay 
for these lifesaving drugs. However, fixed dose combinations, which would decrease the pill 
burden are still largely absent from the deal.  The South African Health Minister Aaron 
Motsoaledi stated that with an estimated saving of about US$685 million from the end of 
January 2011, South Africa could now afford to treat twice as many HIV positive persons 
compared to before the new tender (New ARV tender halves drug prices, 20 Dec 2010).   
Activists from the TAC and Section 27 have welcomed the new tender however they 
continue to call for improvements in the tender’s terms and for greater transparency with 
regard to the tender process.  Jonathan Berger of Section 27 explained that the tender makes 
no provision for a reduction in drug prices should the prices of the active ingredients decline.  
He went on to state that as in past tenders, government has yet to release any documentation 
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about the selection process or how the tender was allocated. TAC and Section 27 call for 
continued actions to drive prices of essential medicines down even further (New ARV tender 
halves drug prices, 20 Dec 2010). The recent global economic crisis has further complicated 
funding and Heywood emphasized that this is not the time for PEPFAR and the Global Fund 
to pull back on funding as the result would be rapid reversal of the ground gained in the fight 
against HIV/AIDS (Aziz, 2010). 
 
2.3  HIV/AIDS Policy, Implementation and MDGs 
The HIV & AIDS and STI National Strategic Plan NSP (2007 -2011), which now includes 
TB heralded the end of a period of confusion, frustration, conflict and anger with regard to 
the goals of the HIV/AIDS policies and marked the beginning of a new chapter of national 
consensus for strategies, policies and legislation that would enable the goals of HIV/AIDS 
prevention and treatment programmes to be achieved (Heywood, 2007). The National 
strategic plan recognizes HIV/AIDS as one of the most pressing challenges facing South 
Africa today. It aims to provide a broad framework to coordinate the work of all key 
stakeholders in response to the challenges of the HIV/AIDS and TB crisis. The document 
views implementation as the collective responsibility of all citizens of South Africa. 
 
 Reducing HIV infection by 50% and increasing uptake of ART to 80% of those in need are 
the overarching objectives of the NSP (UNGASS RSA, 2010). In addition to this, the ten 
point plan or national health system priorities (2009-2014) that aims to transform the health 
care system into a well functioning health system capable of improving the health status of all 
South Africans, signals governments attempt to honour the 2009 electoral mandate of 
improving the health care profile of all South Africans.  Government has also committed to 
attaining the Millennium Development Goals by 2015 which include: eradicating extreme 
poverty; achieving universal access to primary education; promoting gender equality and 
empowering women, reducing child mortality, improving maternal health, combating 
HIV/AIDS, malaria and other diseases, ensuring environmental sustainability and developing 
global partnership for development.  
 
The HIV & AIDS and STI National strategic plan for South Africa 2007-2011, the 
Tuberculosis Strategic Plan 2007-2011 and the ten point plan have been well received by all 
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sectors of South African society.  The publication of these comprehensive documents 
demonstrates that South Africa is certainly not deficient in policy. South Africa may describe 
their health policy as supportive; however, concern has been raised about the capacity of the 
public health system to implement such policy. Sewankambo and Katamba (2009) assert that 
despite an increase in investments and improved social and health policy, South Africa has 
not adequately addressed health disparities which have their roots in the past. The reasons 
according to Sewankambo and Katamba (2009) are an inadequately prepared health-care 
system to address the changing burden of disease; poor leadership, stewardship, and 
management; insufficient human-resource capacity and poor surveillance. South Africa 
therefore appears to be lagging behind in millennium development goal achievement as well, 
especially with regard to maternal and child health and HIV/AIDS as maternal and child 
health is mostly associated with HIV/AIDS.  The Zuma administration’s commitment to 
attaining the MDGs signals government’s attempts to make inroads into the epidemic and 
some progress has been made as evident in the latest UNGASS RSA 2010 report.  For 
example, programme implementation include the mass testing campaign that came into effect 
in April 2010, male circumcision has been adopted as a prevention strategy and the task of 
shifting ART cases from doctors to nurses are some of the strategies that have been put in 
place.  
 
Millennium Development Goal (MDG) 6 seeks to achieve universal access to treatment for 
HIV positive persons who need it, and to halt and begin to reverse the incidence of major 
diseases such as HIV/AIDS, TB  and malaria. The HIV and AIDS,  TB and STI  (NSP) for 
South Africa has similar goals which are to achieve a 50% reduction in HIV incidence rates 
and to achieve 80% treatment coverage for those in need of HIV treatment. The targets for 
the TB strategic plan are a 70% TB case detection rate 85% cure rate and 85% TB treatment 
success rate (SAHR, 2010).   
 
The SAHR (2010) gives an explanation on what needs to be done in order to meet the goals 
of the NSP.  According to SAHR (2010), countries need to know their epidemic and they 
need to customize their responses to the epidemic accordingly.  This means gathering 
information about prevalence rates, incidence rates, most at risk populations and factors 
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contributing to the spread of HIV/AIDS. Strong health information systems and surveillance 
are critical for generating this type of information (SAHR, 2010).  
 
With regard to available prevention interventions the ABC remains the foundation of HIV 
prevention but two additional Cs have been added to the ABC campaign and these are 
knowledge of HIV status through Counselling and HIV testing and medical Circumcision. 
Many woman are still not able to negotiate safe sexual practices and the Caprisa tenofovir 
microbicide trial provides hope for woman-initiated prevention methods.   
 
The SAHR (2010) further states that even though South Africa has the largest ART 
programme in the world questions remain about whether it is reaching the levels of coverage 
needed to see population level reversals in morbidity and mortality trends. 
 
The SAHR (2010) also reminds us that a key gateway to prevention and treatment services is 
knowledge of HIV status and this remains relatively low in South Africa. This is the rationale 
for the implementation of the South African national HIV counselling and testing programme 
(SAHR, 2010).   
 
Some of the reasons cited for South Africa’s failure to deliver lies with the limited routine 
surveillance data available to monitor progress on targets and the fact that South Africa 
appears to have limited ability to identify bottlenecks for service delivery and coverage 
nationally, provincially or at a clinic level.  Also limited discussion occurs at the level of 
service delivery to set targets and timelines.  This disconnect between policy, implementation 
and evaluation is a major obstacle to achieving the NSP goals (SAHR, 2010). South Africa 
appears to have the political will to fight HIV/AIDS and TB but South Africa does not appear 
to have the capacity to carry out its mandate. 
 
South Africa faces enormous challenges with regards to the intertwined HIV/AIDS and TB 
epidemic.  TB is the leading cause of death among people living with HIV and accounts for 
approximately 13% of AIDS deaths globally. HIV and TB are often referred to as dual 
epidemics or co-epidemics as these epidemics drive and reinforce one another.  HIV activates  
16 
 
dormant  TB in a person because of immune suppression and this person becomes  infectious 
and is able to spread the TB bacillus to others (WHO  TB/HIV facts, 2009). 
 
In order to fully comprehend the challenge that the HIV/AIDS epidemic poses it is important 
to acquire a reasonable amount of knowledge and understanding about the human 
immunodeficiency virus and how this virus infects and affects its host. The natural history 
explains the disease in the host, gives insight into how the disease progresses and helps in 
determining when therapy should be initiated.  It must be emphasized that ART also 
contributes to prevention as strict adherence results in a negligible viral load which decreases 
transmission of the virus. 
 
2.4  The Natural History of HIV Infection (without ART intervention) 
The human immunodeficiency virus (HIV) targets the cell of the human host’s immune 
system, in particular the CD4 (helper) T-lymphocytes and begins the gradual process towards 
the destruction of the immune system.  Over time, usually a period of years, the immune 
system gradually weakens and eventually the immune suppression is so severe that the person 
can no longer fight infection and thus becomes vulnerable to opportunistic infections and 
certain types of cancer (Wilson, Naidoo, Bekker, Cotton & Maartens, 2002).   
 
The way in which individuals respond to HIV infection varies widely.  A small proportion of 
individuals experience severe seroconversion illness associated with high levels of viral 
replication followed by a steep decline in CD4 cell count leading to rapid immune system 
destruction and death within a year or two. The majority of HIV infected persons are able to 
regulate viral replication for years because of an effective immune system response. 
However, over time they will endure a steady decline of CD4 cells and the eventual 
destruction of their immune system. A select small percentage of persons infected with HIV 
infection are able to control viral replication effectively with normal or robust immune 
system functioning. These individuals do not experience immune system destruction over 
time, their CD4 cell counts remain at functionally normal levels and they appear to not need 




Before the advent of antiretroviral therapy, the median time to acquired immune deficiency 
syndrome (AIDS), from the time of infection as described above was 8 to 10 years in 
developed countries. Socio-economic conditions like malnutrition and poor access to quality 
health care may cause the natural history in developing countries to be shorter.  Age is a very 
important demographic factor because older persons tend to progress more rapidly to AIDS 
than their younger counterparts (Wilson et al., 2002; Natural history of HIV, 2007). 
 
Antiretroviral therapy has without doubt altered the natural history of HIV infection 
progression in a most efficacious way (Natural history of HIV, 2007). Before the researcher 
explains how antiretroviral therapy works it is necessary to explain how health care 
professionals determine the prognosis of HIV/AIDS infection in an individual.  
 
The WHO developed a staging system which is a system of criteria, or list of symptoms 
which help health care professionals decide which of the four stages of HIV infection the 
person finds himself or herself in.  This is particularly important in resource-limited settings 
as this enables health care workers to determine the appropriate time to start treatment.  Often 
poor regions do not have the capacity to follow through with the blood tests that are more 
accurate in determining prognosis and when to initiate treatment. 
  
2.5  Prognosis and Staging 
Wilson et al. (2002) explain that individual prognosis is best determined by a combination of 
a clinical evaluation of the person’s immune status with information provided by the CD4 
count and viral load (VL). These authors further state that the information can be used to give 
the person knowledge to make important personal and social decisions to determine when to 
initiate ART and opportunistic infection prophylaxis, or as a guide to palliative care.  
Prognostic information gives an overall view of the risk of disease progression in large 
numbers of people and it is important to remember that individual disease progression may 
vary (Wilson et al., 2002). 
 
The World Health Organisation’s (WHO) staging system for HIV infection uses standard 
criteria to help clinicians evaluate immune system function and to assess HIV disease 
progression. The Centers for Disease Control and Prevention’s classification system (CDC) is 
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newer and is widely used in developed countries and is described as the cornerstone of 
HIV/AIDS diagnosis  (Natural  history of  HIV, 2007).  WHO  describes  four  clinical stages  
which   are further elaborated in Appendix 2.  Appendix 3 displays the CDC classification 
system. 
 
2.6  Background to Public Antiretroviral Therapy Availability 
South Africa’s failure to prevent the rapid growth of the HIV/AIDS epidemic in the 1990s 
and delays in implementing a treatment programme in the early 2000s can only be described 
as a gross violation of basic human rights. During the denialist period, thousands of babies 
were denied lifesaving preventative ARVs and thousands of lives were lost because ARVs 
were simply not made available for treatment in the public sector. The Treatment Action 
Campaign (TAC) was founded in 1998 in response to the need for an organisation that would 
campaign for the rights of people living with HIV and to demand access to HIV treatment in 
South Africa for all who were in need of it.  What is ironic is that the Deputy President at that 
time, Mr Thabo Mbeki who launched the Partnership against AIDS admitted that 1500 new 
infections were occurring every day, yet he would during his tenure as president prefer 
dissident views on HIV rather than sound evidence based scientific views on HIV. President 
Mbeki rejected the link between HIV and AIDS and blamed the growing HIV/AIDS 
epidemic on poverty. The most rapid increase in HIV prevalence in South Africa took place 
between 1993 and 2000 amidst confusion, denialism and major political change (Avert. HIV 
& AIDS in South Africa, undated). 
 
A milestone in the battle for ART came in 2001 when a high court decision in favour of the 
TAC forced the South African government to make ART for the prevention of mother to 
child transmission of HIV available in the public sector. Attention then focussed on providing 
ART for all those in need of this lifesaving medication.  The TAC used mass action to 
highlight its cause and to force the government to commit to providing ART.  The South 
African government continued to drag its heals with regard to ART provision. Eventually the 
announcement to provide ART to persons who accessed public health care was made at the 
end of 2003. The South African Department of Health promised the implementation of the 
national ART rollout by March 2004. Under global and national pressure especially from the 
Treatment Action and other civil society organisations treatment guidelines were issued in 
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September 2004.  It took another few months (until March 2005) for suppliers of ARVs to be 
chosen. The roll-out gathered pace from mid 2005 although the number of people receiving 
treatment lagged behind the operational plan targets (Avert. History of HIV & AIDS in SA, 
undated).  Zachie Achmat and the TAC were joint nominees for a Nobel prize in 2004 for the 
organisations steadfast fight for the provision of ART for the people of South Africa. 
 
2.7  HIV/AIDS Antiretroviral Therapy (ART) 
The human immune deficiency virus (HIV) can be divided into two types: HIV-1 responsible 
for the global epidemic and HIV-2 which is less pathogenic than HIV-1 and is largely 
restricted to West Africa with limited spread to other countries (Wilson et al, 2002).  HIV-1 
virus is a rapidly evolving virus (mutates rapidly with high replication rate) which means that 
HIV has the ability to escape detection by the host immune system and HIV can rapidly 
develop resistance to antiretroviral agents. To minimize the risk of resistance, a potent 
combination of at least three anti retroviral agents are prescribed to maximally suppress HIV 
viral replication at different stages of the life cycle of the virus halting the progression of  
HIV disease to improve clinical outcomes (Satyanarayana & Srivastava, 2010).  Suppression 
of the virus is the only way to prevent the progression of HIV infection to AIDS.  This 
process allows for reconstitution of the CD4 T cell population and restoration of the immune 
system. This can only be accomplished by taking the treatment regimen exactly as prescribed 
(Orrell, 2008).  Treatment regimen, drug ‘cocktail’, highly active antiretroviral therapy 
(HAART) are all synonyms for HIV antiretroviral therapy.  
 
The persistence of HIV reservoirs means that ART cannot eradicate HIV.  ART may not be 
able to eradicate HIV but ART can reduce the viral load (VL) to negligible amounts, enable 
restoration of the immune system and maintain this status for as long as possible as 
eventually resistance will set in and a regimen change will be necessary (Mahungu, Rodger & 
Johnson, 2009; Noë, Plum & Verhofstede, 2005). 
 
There are currently over 30 ARVs globally and these include NRTIs, NNRTIs,  PIs ( Protease 
inhibitors), the new Fusion inhibitors, Entry inhibitors-CCR5 co-receptor antagonists and 
HIV integrase strand inhibitors.  These drugs are available as either single drugs or fixed dose 
combinations (FDCs) (Satyanarayana & Srivastava, 2010). The newer drugs usually have less 
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adverse side effect profiles, are simpler to take (reduced pill burden, lesser food restrictions, 
no refridgeration), and generally fit in more easily to a person’s lifestyle, in other words 
treatment is simplified. Antiretroviral combinations available in the South African public 
sector national programme before the new guidelines made accessible on 1 April 2010 
included the first line regimen of stavudine, lamivudine and efavirenz or nevirapine (for 
pregnant females) and the second line regimen of didanosine, zidovudine and 
lopinavir/ritonavir. Clinical criteria for treatment before the April 2010 changes was a CD4 –
T cell count below 200cells/mm³, WHO stage 3 or 4 or both for all persons in need of 
treatment. The treatment combinations include two nucleoside reverse transcriptase inhibitors 
(NRTI) and either, a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease 
inhibitor (PI), or other such combinations (Cichochi, 2008).  
 
2.7.1  New Antiretroviral Therapy (ART) Guidelines 
The long overdue new treatment (last updated in 2004) for South African finally came into 
effect on the 1 April 2010.  These updated guidelines are available on the SANAC (South 
African National AIDS Council) website (www.sanac.org.za).  The new HIV/AIDS treatment 
guidelines complement existing HIV/AIDS and TB management guidelines, and are the 
result of extensive consultation through the SANAC Treatment Technical Task Team 
(Department of Health RSA & SANAC, 2010). 
 
HIV positive pregnant women and person’s co-infected with HIV and TB are now eligible for 
lifesaving treatment much earlier (CD4 T cell count less than or equal to 350).  Early 
treatment is available to all HIV positive infants and improved regimens to prevent mother to 
child transmission is available to pregnant women. Other notable changes include the phasing 
out of stavudine (because of the long term adverse side effects namely, lipodystrophy and 
neuropathy), and replacing it with tenofovir, which has a much lower adverse side effect 
profile. 
 
TAC Equal June 2010 reports that South Africa faces a major barrier to improving treatment 
regimens because of low registration of drugs by the Medicines Control Council (MCC).  
Many essential drugs in the new treatment guidelines have not been approved by the MCC, 
particularly fixed dose combinations and paediatric formulations.  The Southern Africa HIV 
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Clinicians Society has called on the MCC to fast track the registration of a number of ARV 
drugs, particularly tenofovir fixed dose combinations as well as abacavir/lamivudine 
combinations and lopinavir/ritonavir paediatric formulations. Fixed dosed combinations are 
recommended by most health care professionals and the Southern African HIV Clinicians 
Society because the lower pill burden is associated with improved adherence (TAC Equal, 
June 2010). 
 
Poor treatment adherence leads to increased drug resistance, meaning a switch to the more 
expensive second line and third line treatment (TAC Equal, June 2010).  The public sector 
rollout currently offers first and second line treatment options, therefore it is most important 
that the first line treatment regimen be preserved for as long as possible (Orrell, 2008). The 
first line options are potent drug combinations which are easier to take as they have a much 
lesser side effect profile than second line options (Soul City, Jacana Media, Health & 
Development Africa, 2005).  Orrell and Wilson (2003) further emphasise that the first line 
options are the ones most likely to have success because once exposed to antiretroviral 
therapy subsequent regimens may have poorer clinical benefits. A person’s best chance of 
combating HIV and living a healthy life is with the first line treatment. Stringent adherence to 
the prescribed treatment regimen is a prerequisite for optimal health outcomes. The public 
health sector aims to provide a standard of health care in keeping with the principles of Batho 
Pela that is cost effective, efficacious and of good quality. 
 
2.7.2  Comments on the New Antiretroviral Therapy (ART) Roll-out 
The new treatment guidelines are a step in the right direction but they still lag and  fall short 
of the latest WHO ART guidelines which clearly states that all HIV positive people should be 
starting ART at a CD4 count of about 350cells/mm³.  A CD4 count of 350cells/mm³ should 
be considered a ‘minimum standard of care’ for commencing ART, a statement supported by 
the WHO and the European and British AIDS societies.  The USA recommend higher levels 
for treatment initiation at a CD4 count of 500cells/mm³ (Rossouw, Richter, Martin, Avenant 
& Spencer, 2011).  According to the new South African guidelines, only pregnant mothers 
and person’s co-infected with TB are eligible for ART at a CD4 cell count of about 
350cells/mm³, other adults get ART at a CD4 count of 200cells/mm³ or if they present with 
opportunistic infections or clinical staging that can motivate for ART earlier. 
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It must be stated  that there is a  discrepancy as to when ART is made available  in  the public  
sector and the private sector in South Africa. The private sector practitioners may use their 
own discretion based on the latest available data on when best to initiate ART. The public 
sector appears to compromise to provide reasonable and affordable health care for the 
majority of people in need of health care.   
 
Another comment on the new guidelines was that tenofovir needs to replace stavudine for all 
people on Regimen 1, not only new people who are accessing treatment.  WHO recommends 
that stavudine be phased out due to concerns over “long-term, irreversible” side effects that 
include lipodystrophy and peripheral neuropathy, and other serious side effects such as lactic 
acidosis (WHO Press release, 30 Nov 2009). 
 
In  April 2010 the TAC, Southern African HIV Clinicians society and other civil society 
groups lobbied for the new first line treatment to be updated to include tenofovir based three-
in-one once daily pills because this is affordable, has a lesser side effect profile and is easier 
to take, enhancing treatment adherence (TAC, Equal. April 2010). The activists also called on 
the health department to commit to procuring FDCs where available and for the MCC to fast 
track the registration of all ARVs and combinations of ARVs so as to ensure a competitive 
tender. The MCC refused to fast track critical fixed dose combinations (FDC) for inclusion in 
the country’s massive antiretroviral tender announced in December 2010.  There were no 
FDCs included when the tender outcome was announced and this fact went virtually 
unnoticed as people applauded the massive price reductions announced by health minister Dr 
Aaron Motsoaledi  (Thom, 2 Feb 2011). 
 
South Africa has the largest ARV programme in the world and FDCs could have made a 
massive difference especially in settings with few doctors, nurses and pharmacists. FDCs 
improve the likelihood for good adherence and maintenance of viral suppression which leads 
to better treatment outcomes. FDCs also just make the process of dispensing and recording so 
much easier especially in resource constraint settings which is in abundance in South Africa 
(Thom, 2 Feb 2011). 
 
The  advent of  HAART  ushered in a new era in the  lives of people infected with the  human 
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 immune deficiency virus.  HIV infection was no longer a life-threatening illness, it 
transformed into a manageable chronic condition.  Millions of people worldwide were given 
hope of fulfilling their life goals as a relatively normal life became a distinct possibility. 
 
2.7.3  Goals of Antiretroviral Therapy (ART) 
Machtinger and Bangsberg (2006) state that in countries with broad access to antiretroviral 
therapy the clinical benefits of treatment have been dramatic.  Far fewer people were 
progressing to AIDS and hospitalisation for AIDS related illnesses decreased dramatically.  
 
Benefits or goals of ART are: 
• Maximal and durable suppression of HIV viral replication to undetectable levels.  
• Restoration and preservation of the immune system, eliminating the risk of 
opportunistic infections and preventing opportunistic infections (Moosa, 2007). 
• Reduction of HIV related morbidity and mortality - halting the disease progression, 
improvement in the quality of life and the conversion of HIV/AIDS to a chronic 
disease. 
• Preventing the emergence of drug resistant strains of HIV thus protecting the 
available antiretroviral treatment agents and not compromising the available treatment 
options (Public sector ART treatment options are limited to two regimens). 
• Potentially reducing the transmission of HIV: reducing transmission in serodiscordant 
couples, reducing mother to child transmissions and impacting positively on the 
incidence of HIV infection (Dawood, 2007, The Art of HAART). 
 
The results of the HPTN 052 study  released in May 2011 proved conclusively that ART use 
in serodiscordant couples reduced infection rates by 96% confirming that treatment is 
prevention (Sax, May 12, 2011). 
 
2.7.4  Benefits and Risks of Early and Deferred Treatment 
ART should preferably not be started as a matter of urgency. Persons in need of treatment 
should have enough time to gain sufficient knowledge about HIV so that they can make 
informed choices about managing their condition.  Some people choose to delay the start of 
therapy for as long as they can safely do so whereas other people appear eager to start therapy 
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earlier in the course of HIV disease.  Unfortunately most South Africans seem to get to know 
their status and access treatment at a late stage in disease progression (CD4 well below 200 or 
when they present with an opportunistic infection) (SANAC, Midterm Review, 2010). In 
these cases there is clearly no time to contest the matter as their health is already severely 
compromised and fast track access to ART is their only salvation (Dawood, The Art of 
HAART, 2007). 
 
2.7.4.1  Benefits and Risks of Early ART 
Benefits      Risks                  
Early suppression of viral replication. Drug related reduction of quality of life 
because of drug side effects. 
Preservation of immune system function. Earlier development of drug resistance if 
complete HIV suppression is not achieved. 
Lowers risk of drug resistance if HIV 
reproduction is sufficiently suppressed. 
Fewer future treatment options if HIV 
develops resistance to drugs used early. 
Decreased risk of HIV transmission.  
 
   
2.7.4.2  Risks and Benefits of Deferred ART 
Benefits      Risks 
Avoids negative effects of ART on quality of  
life. 
Possible irreversible immune system 
depletion. 
Avoids drug-related adverse effects. 
 
Possibly greater difficulty in suppressing viral 
replication. 
Delays development of drug resistance. 
 
Possible increased risk of HIV transmission. 
 
Preserves future treatment options. 
 
More drug related adverse effects and health 
problems. 






2.8  Antiretroviral Therapy (ART) Adherence  
Medication adherence may be defined as the extent to which a person takes a medication in 
the way intended by a health care provider (Machtinger & Bangsberg, 2006).  Persons on 
HAART require adherence rates of  greater than 95% to obtain the full clinical benefit of 
their medication as near perfect adherence is a critical determinant of treatment success 
(Orrell, 2008; WHO, 2003).  This means taking medication exactly as directed: on time, all 
the pills, no missed doses, everyday, for the rest of their lives (Orell, 2004).  No other chronic 
medication requires such stringent adherence for optimal therapeutic benefit, which may 
mean the choice between life and death. The extremely rapid replication and mutation rate of 
HIV means that very high levels of adherence are required to achieve durable suppression of 
the viral load to undetectable levels (WHO, 2003; Moosa, 2007). WHO (2003:95) further 
asserts that “these multidrug regimens although highly efficacious, results in HIV treatment 
having the most complicated regimens that have ever been prescribed for conditions requiring 
continuous open-ended treatment”. 
 
According to Catherine Orrell (2008) in her discussion on the importance of HAART 
adherence, achieving adherence rates of 95 – 100% poses a very real challenge.  From 
information about adherence rates for other chronic diseases such as diabetes and asthma it is 
known that persons on treatment seldom manage to achieve a 95% adherence rate. Typical 
adherence rates for medications prescribed over long periods are in the range of 50 – 75% 
(Machtinger & Bangsberg, 2006).  HAART adherence has therefore emerged as both a major 
determinant and the “Achilles Heel” of treatment success as HAART adherence is the second 
strongest predictor of progression to AIDS and death after CD4 count (Machtinger & 
Bangsberg, 2006:2). 
 
Adherence to HAART is not the only determinant of treatment success or failure: genetic 
differences in drug metabolism, severe baseline immune system suppression, prior drug 
resistance, eventual/acquired drug resistance and concurrent episodes of opportunistic 
infections may all be contributing factors.  However HAART adherence remains an 
important potentially alterable factor in determining treatment outcomes of HIV infected 
people (Machtinger & Bangsberg, 2006).  
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Orrell and Wilson (2003) explain that successful therapy is critically dependent on the HIV 
clinician and the person in need of treatment establishing a robust therapeutic relationship.  
The doctor must take responsibility for prescribing medicine that will suit the person’s 
lifestyle and must provide support for the person.  The person must accept the need for 
lifelong  adherence to  therapy  and  must understand  both the  risks and  benefits offered  by  
ART (Orrell & Wilson, 2003). 
 
The National HIV roll-out programme guidelines expresses the need for a more holistic 
approach to health care management, namely the Team Centred Approach, a shift from 
doctor led care. Each member of the health care team is crucial to the success of the person in 
need of care and decisions should be made about the person as a team. Regular meetings with 
all team members enable input from all the disciplines and in this way the team views the 
problem in a more holistic way and gets a better understanding of the context in which the 
problem occurs. The team should be multidisciplinary comprising of, for example, medical 
officers, nursing staff, lay counsellors, pharmacists, social workers, psychologists, dieticians 
and administration workers (Dawood, National roll-out programme guidelines, 2007). 
 
2.8.1  Adherence Rates in Southern Africa 
The high rates of adherence observed in Soweto, South Africa, compare favourably with 
adherence rates in developed countries.  This may be due to greater motivation of South 
Africans in need of antiretroviral therapy because of the history of scarce access to  
antiretroviral therapy and because the disastrous effects of AIDS are seen everywhere in their 
everyday lives (Mills, Nachega, Bangsberg et al., 2006; Nachega, Stein, Hlatshwayo,  
Mothopeng,  Chaisson & Karstaedt, 2004). 
 
Mills, Nachega and Buchan et al., (2006) in their analysis of developed and developing world 
HIV adherence, found that there are people in both settings that have sub-optimal adherence, 
and that factors beyond poverty play a role. This analysis of adherence to antiretroviral 
therapy in Sub-Saharan Africa and North America revealed that expectations of poor 
adherence in Africa is not  an evidence based rationale for delaying expansion of ARV 
treatment programmes in resource poor settings.  The Mills, Nachega and Buchan et al., 
(2006) study found relatively high levels of adherence in resource poor setting therefore 
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effort should be directed towards interventions that will aid maintenance of these adherence 
rates.  Understanding culturally specific barriers to adherence may be important in 
developing evidence based strategies targeted at individuals who are poor adherers to their 
HIV medication (Mills, Nachega, Buchan et al., 2006). 
 
2.9  HIV as a Chronic Disease 
Diseases are usually classified as either  acute, chronic or terminal.  An acute illness lasts for 
a short period of time and may go away without any intervention, medication or surgery, a 
chronic disease recurs or persists for a long period of time or may last for a person’s entire 
lifetime and terminal means that death or nearing the end of life is approaching. Chronic 
diseases can only be controlled; they cannot at present, be cured. These diseases are among 
the most common, costly and preventable of all health problems and examples include 
diabetes, heart disease and now HIV/AIDS (Department of Health UK, 2004). 
 
“There is no doubt that HAART is one of the most celebrated treatment advances in recent 
medical history” WHO (2003:95).  Highly active antiretroviral therapy (HAART) is not a 
cure for HIV infection but can be hailed as responsible for the transition of HIV/AIDS from a 
life threatening terminal illness to a chronic manageable disease (Gifford & Groessl, 2002; 
Meyer & Ogunbanjo, 2006; Nishal, Khopkar & Saple, 2005; Lucas, 2005).  HIV as a chronic 
disease means that HIV infected persons may now look forward to living a long and 
relatively healthy life provided their medical condition is optimally managed or controlled. 
 
Gifford and Groessl (2002) assert that the care of chronic diseases such as diabetes, asthma 
and now HIV infection is profoundly different from caring for an acute illness.  Chronic 
disease management usually implies lifelong treatment, and the treatment must be sustainable 
if the therapeutic goals of the treatment are to be achieved. The management of chronic 
disease can be described as much more than prescribing medication and giving advice. 
Effective health care providers have the additional tasks of providing the person in need of 
chronic care with the necessary tools, knowledge, skills and motivation to sustain life-long 
treatment (Mahungu et al., 2009).  Treatment with HAART has brought along with it other 
challenges and these include amongst others the unknown long-term history of treated HIV 
infection, the development of toxicity and drug resistance and the ageing HIV infected person 
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(Mahungu et al., 2009).  The British HIV Association (BHIVA) together with the Royal 
College of Physicians, British Association for Sexual Health and Infection and HIV Infection 
Society recently published Standards for HIV clinical care.  According to this report, people 
with HIV infection are best managed within chronic care disease models. The report also 
makes recommendations on the level of service provision expected from centres providing 
HIV care and the level of professional expertise required from health care providers. Chronic 
disease management is a challenge and a model for managing chronic disease enables the 
health system to respond to the challenge in an appropriate, systematic and cost effective 
way. Some of the key components of chronic disease management includes early detection, 
prevention and optimising treatment response (Mahungu et al., 2009).   
 
Almost all HIV positive persons will eventually need antiretroviral therapy.  Near perfect 
ART adherence is required for optimal health outcomes.  It is therefore necessary to explore 
the factors that influence adherence to HIV medication.  Information so gleaned may help 
health care providers and persons on ART to better understand how various factors influence 
adherence and so inform strategies that will positively influence adherence behaviour. 
 
2.10  Factors that Influence Adherence to HIV Medication 
Gray and McIntyre (in Van Dyk, 2005) propose that adherence is a complex issue determined 
by factors related to the person, the disease process and stage, the treatment regimen, the 
interaction between the person and the health care worker and the environment in which the 
person resides. As stringent adherence to ART is crucial to treatment success, Van Dyk 
(2005) gives some examples of the kind of questions that should be asked in order to gain 
greater insight into the factors that may influence adherence. This may give the health care 
worker an indication of the person’s ability to adhere to ART as well as  inform strategies 
that need to be developed in order to help the person maximise their chances of successful 
treatment (Van Dyk, 2005). 
 
The Person 
• Is the person motivated to take ART? 
• Does this person have adequate social support? 
• What are his/her beliefs about sickness and health? 
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• How did this person take other prescribed medication, like antibiotics or TB 
treatment? 
• Does this person have adequate coping skills? 
• What is the cognitive level of this person? 
• Will this person be able to follow a stringent adherence schedule? 
 
The Treatment Regimen 
• How many pills and how often will these pills have to be taken? 
• How does the medication taste and are they easy to swallow? 
• What about the dietary requirements for taking the pills? 
• What side effects might be experienced and how will the person deal with them? 
• What about medication the person is taking for other conditions and possible drug 
interactions? 
 
The Relationship between the Person and the Health Care Worker/s 
• Has a relationship of trust developed between the health-care worker and the person? 
• Will the person receive adequate support from the health care worker/s? 
• Does the care worker take time to give adequate explanation about the adverse side 
effects that may be experienced? 
• Is the health care system providing a satisfactory level of service? 
 
Environment 
• Are the health care services adequate and accessible to the person? 
• Is transport to these services satisfactory and easy to access? 
• Does this person have access to a reasonable supply of medication? 
• Does this person have access to the necessary dietary requirements for taking 
medication? 
(Van Dyk, 2005). 
 
Pratt (2003) explains that for most people on ART, patterns of adherence vary with the 
circumstances of their lives.  He further states that few people claim to be 100% adherent; 
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most people are adherent 70-99 percent of the time, and about 30 percent are poor adherers, 
taking less than 60 percent of their medication. Adherence or non-adherence is therefore 
dynamic, changing or varying according to circumstances in their lives at particular points in 
time.  Pratt (2003) points out that there are a number of factors that need to be considered by 
healthcare personnel and persons on ART in order to promote adherence and give persons on 
ART the best possible benefit of their medication sustained viral suppression. Factors relating 
to the regimen, the person’s lifestyle, available social support and the person’s knowledge 
and understanding of treatment may positively or negatively influence adherence behaviour. 
Pratt (2003) also explains the influence of the health care providers, with particular emphasis 
on the nursing role in supporting adherence.  
 
The factors that Robert Pratt (2003) explain are included in the World Health Organisation 
discussion on adherence and are therefore incorporated into the discussion below in order to 
avoid repetition. The World Health Organisation (2003) argues for a systems approach to 
studying adherence thus adherence is viewed as a multidimensional phenomenon determined 
by the interplay of five sets of factors or dimensions: social and economic factors; therapy 
related factors; condition related factors; person related factors and health care team and 
system related factors.  A systems approach encourages a holistic view and this involves a 
conscious effort to understand how the various factors impact upon adherence behaviour. 
 
2.10.1  Socio-economic Factors 
Socioeconomic factors such as socio-economic status, education level, literacy, income and 
housing status are generally not predictive of adherence (Meyer & Ogunbanjo, 2006; WHO, 
2003).  However, low socioeconomic status may put persons on medication in a position 
where they may have to choose between competing priorities, for example, they may have to 
direct limited resources to meet the needs of other family members such as children or 
parents for whom they care (WHO, 2003).  
 
Socioeconomic factors that  are reported to have a significant  effect on adherence  in  certain  
circumstances are poor socioeconomic status, low levels of education, unstable living 
conditions, inadequate social support networks, long travelling distance to and from the 
treatment centre, transport costs, dysfunctional family systems, culture and lay beliefs about 
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the disease and treatment, high cost of medication and the changing environment (WHO, 
2003). Heyer and Ogunbunjo (2006) contend that educational level, literacy, income and 
housing status are not consistently predictive of adherence because in the twenty two studies 
evaluated by Fogarty, Roter,  Larson, Burke, Gillespie and Levy (2002) only five 
demonstrated a correlation between socio-economic factors and adherence. Heyer and 
Ogunbanjo (2006) report that a South African study by Orell, Bangsberg, Badri and Wood 
(2003) found no association between adherence and socio-economic circumstances, asserting 
that adherence rates in developing countries are comparable with adherence rates in 
developed countries, and therefore should not be used as an excuse for limiting antiretroviral 
therapy access to persons in developing countries. 
 
WHO (2003) suggests that race is often reported as a predictor of adherence but it is rather 
cultural beliefs that may lead to poor adherence confounded by social inequalities.  War has 
also been reported to affect adherence to therapy because of the resulting economic hardship, 
lack of medical control, fatalism and anarchy that it brings (WHO, 2003). More insight into 
the influence of social factors is detailed in the paragraph on person factors that influence 
adherence  because of category overlap and to avoid repetition. 
 
2.10.2  Health Care Provider Factors 
The qualities of the health care provider are an important factor in helping persons on ART 
adhere as prescribed (Pratt, 2003).  Qualities such as active listening, being sensitive to the 
persons needs, empathizing, developing an understanding of the persons situation and good 
communication skills are most necessary for recognising the person as a partner in treatment 
decisions and for translating complex medical information  in a manner that is clear and 
understandable to persons on treatment (Pratt, 2003). Pratt further states that a health care 
provider-person relationship of mutual trust and respect is likely to positively influence 
adherence behaviour because persons will feel free to be open and honest about problems 
they may experience with regard to ART adherence. 
 
It is interesting to note that organisational factors may be more related to adherence than 
socio- demographic factors.  Albaz, (in WHO, 2003) concluded that time spent with the 
health care provider, continuity of care by the health care provider and the communication 
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and interpersonal style of the health care provider may be more important for adherence to 
therapy than socio-demographic variables such as gender, status, age, educational level and 
health status. 
 
2.10.3  Health Care System Related Factors 
Factors such as poorly developed health services, inadequate or non-existent health 
insurance, poor medication distribution, lack of knowledge and training of health care 
providers in chronic disease management, overworked health care providers, lack of 
incentive and feedback on performance, short consultations, weak capacity to educate both 
person in need of treatment and health care provider, inadequate community support and 
health care provider support, lack of knowledge on adherence and interventions to improve 
adherence cover some of factors that may contribute to poor medication adherence (WHO, 
2003).  Long waiting times for clinic services were reported as important barriers to a 
person’s ability to return to the clinic for service and to pick up medication. This may be 
stigmatising as additional time off work may be required. Communication barriers may also 
be a cause for concern especially when persons in need of treatment spoke different 
languages to their providers (Dahab et al., 2008). 
 
2.10.4  Condition Related Factors 
These  factors refer to  the  illness  related demands faced  by the  person with  HIV  infection 
determined by the stage and duration of HIV infection, the physiological markers of HIV 
disease progression such as CD4 cell and viral load count, associated opportunistic infections 
and cancers and HIV related symptoms (Machtinger & Bangsberg, 2006;  Vervoort, Borleffs,  
Hoepelman, & Grypdonck, 2007; WHO, 2003).   
 
The stage of HIV disease, severity of opportunistic infections and symptoms present at the 
onset of treatment are factors that may influence adherence either negatively or positively. 
WHO (2003) states that when symptomatic HIV positive persons understand the relationship 
between adherence and viral load, then they are more likely to be adherent.   Orrell (2008) 
states that late or symptomatic HIV disease presentation may promote adherence because 
people experience the beneficial effects of ART as they begin their recovery and regain their 
strength and health.   
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TB and HIV/AIDS  are epidemic in South Africa.   HIV positive persons are more 
susceptible to TB infection because of their compromised immune system. Persons who 
access HIV treatment when they are co-infected with TB and/or other opportunistic infections 
make taking ART even more complicated because of the pill burden, increased drug 
interaction, increased adverse side effect profile, and they are immune-compromised, which 
makes them feel weak, tired and ill. 
 
The latest WHO treatment guidelines recommend initiating ART at a CD4T cell count of 
greater than or equal to 350cells/mm³.   In most cases, at a CD4 of 350-500cell/mm³, the 
person is immune-compromised but not necessarily susceptible to opportunistic infections.  
Taking ART will therefore restore and strengthen  the immune system and the HIV positive 
person is likely to become less susceptible to opportunistic infections such as TB. 
 
2.10.5  Therapy Related Factors 
Treatment related factors that influence adherence are usually associated with the complexity 
of the regimen, previous treatment failures, the immediacy of beneficial results, adverse side 
effects and the support the person receives, both medical and social. Complexity refers to, for 
example, the treatment routine, duration of treatment, the dosing frequency, number of pills 
per dose (pill burden) and special instructions, for example, with or without food or fluid 
(WHO, 2003). The factors mentioned above all have the potential to have a negative effect on 
antiretroviral treatment adherence.  Regarding treatment routine, changes in daily routine or 
being away from home may cause sub-optimal adherence (Aspeling & van Wyk, 2008). 
 
Antiretroviral therapy can cause side effects just like most other drugs that are prescribed. 
The way in which persons on antiretroviral therapy react to their medication varies 
considerably between individuals.  Individuals who start antiretroviral therapy at lower CD4 
T cell counts may be more affected by side effects than those who start therapy at higher 
CD4T cell counts (Soul City, Jacana Media, Health and Development Africa, 2005).  WHO 
(2003) asserts that the literature on side effects shows that optimal adherence occurs with 
therapy that removes symptoms whereas adherence is reduced by therapy that causes side 
effects.  HAART may greatly increase the quality of life in persons who are symptomatic but 
may have a negative effect on the quality of life in asymptomatic persons. Individuals who 
34 
 
were symptomatic when put on treatment usually feel and appreciate the benefits of therapy, 
and are more aware of the implications of non-adherence than individuals who were 
asymptomatic when treatment began (WHO, 2003).   
 
Naidoo (2009) found an association between adherence and difficulties swallowing ART. 
Persons in this study cited difficulty in swallowing as a reason for not being able to take their 
medication. Participants reported that the protease inhibitor regimen appears to be the most 
problematic because of their side effect profile, drug interactions and the food restrictions that 
persons have to contend with when taking this ARV (Naidoo, 2009).  HAART regimens are 
associated with both short-term and long-term side effects.   
 
Short-Term Side Effects:   Most of the short-term side effects occur in the first two to six 
weeks after starting medication. Symptoms like headaches, difficulty sleeping, tiredness, 
nausea, diarrhoea, dizziness, bad dreams or nightmares, mild confusion and rash are common 
and most will settle and disappear once the body has adjusted to the new drugs (Soul City, 
Jacana Media, Health and Development Africa, 2005).   
 
Long Term Side Effects:  The long-term side effects are those that become evident after a 
few years on treatment. They are also the effects of long-term therapy that health care 
providers are learning about as persons stay on therapy for longer and longer periods. The 
common long term side effects to date include peripheral neuropathy, lipodystrophy, liver 
damage, pancreatitis, lactic acidosis, increased triglycerides and cholesterol, increased 
glucose levels, and anaemia.  Lipodystrophy is not life threatening but is aesthetically 
difficult to cope with whereas lactic acidosis may be life threatening. Lactic acidoses 
indicates increased levels of lactic acid in the blood which is harmful to cells of the body.  
This may be due to ineffective functioning of the mitochondria (the power house of the cell) 
and interfere with the energy requirements of body cells.  Therefore careful monitoring of 
persons receiving antiretroviral therapy is crucial. Lipodystophy means disturbance in body 
fat metabolism and involves changes in the way body fat is distributed in the body.  Persons 
who are affected by this side effect show signs of wasting or decrease in fatty tissue on the 
face, arms, buttocks and legs and increase in fatty tissue around the waist, in the breasts and 
the buffalo hump (a lump of fat on the back, just below the neck (Soul City, Jacana Media, 
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Health and Development Africa, 2005).  It is important to note that physiologically these 
physical deformities are usually preceded by insulin resistance, hyperglycaemia (sugar 
metabolism abnormalities) and hypercholesterolaemia and hypertrigliceridaemia (lipid 
abnormalies). The exact relationship between these physiological changes to lipdystrophy is 
unclear but these physiological abnormalities are side effects that are potentially harmful and 
need to be treated accordingly (WHO, 2003; Moosa, 2007). Peripheral neuropathy refers to 
nerve ending damage at extremities such as feet and hands and persons may experience 
tingling and numbness in the hands and feet as well as a burning sensation, shooting pains, 
throbbing, aching or “pins and needles” (Soul City, Jacana Media, Health and Development 
Africa, 2005).   
 
Persons on therapy may decide to discontinue therapy or request and sometimes insist on 
medication changes if they experience side effects that they deem are too problematic to 
accommodate (WHO, 2003).  Distressing side effects such as fatigue, diarrhoea, stomach 
pain and nausea can be treated successfully. However there is no available treatment for 
lipodystrophy and a drug swop may be necessary accompanied by dietary advice and exercise 
to lessen the impact of this side effect (Heyer and Ogunbanjo, 2006).   
 
Persons on antiretroviral treatment must be educated about the potential adverse side effects 
they may experience and be advised on how to handle them (Moosa, 2007; Vervoort et al., 
2007).  It must be emphasised that antiretroviral therapy works, is well tolerated by the vast 
majority of persons in need, and most side effects are manageable (Moosa, 2007). WHO 
(2003) reiterates the importance of simplified regimens for optimal adherence.  Regimens 
with fewer pills, fewer doses and a minimal side effect profile are most desirable for 
achieving maximum adherence. 
 
2.10.6  Person Related Factors 
Person-related factors reported to affect adherence may include, amongst others: 
forgetfulness; psychosocial and/or psychological stress; anxieties about adverse side effects 
of ART; low motivation; inadequate knowledge and skill in symptom and side effect 
management and treatment; lack of perceived need for treatment; misunderstanding and non-
acceptance of HIV disease; disbelief in the diagnosis; negative beliefs in the efficacy of 
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treatment; inadequate monitoring; misunderstanding of treatment instructions; low attendance 
for follow-up counselling and support sessions; hopelessness and negative feelings; 
frustration with the health care providers; fear of dependence on the health care system;  
anxiety over the complexity of treatment regimens and  fear of stigmatisation and 
discrimination associated with HIV disease (WHO, 2003).  Psychosocial factors may include 
mental health, substance abuse and social support as well as socio-demographic factors such 
as age, gender, income, race/ethnicity, education, literacy, housing status and medical 
insurance status.  
 
WHO (2003) gives insight into the complexity of adherence behaviour when explaining that 
the persons knowledge and beliefs about HIV disease, motivation to manage it, confidence in 
their ability to elicit the necessary behaviour,  knowledge and understanding of treatment 
outcomes, and the consequences of non-adherence, interact in ways that are truly complex, 
and not always clearly understood.  The statement becomes more apparent as it becomes 
clear that a factor or factors that may be a stumbling block to one person on treatment may 
not necessarily be one for another person and vice versa. 
 
Williams and Friedland (1997) and Meyer and Ogunbanjo (2006) state that characteristics 
such as age, sex, race/ethnic group, gender, education, occupation and socioeconomic status 
appear consistently non-predictive of a person’s ability to adhere optimally to antiretroviral 
therapy. Machtinger and Bangsberg (2006) found that most studies on factors that influence 
adherence report conflicting evidence about the association between socio-demographic 
factors and adherence behaviour.  However when an association is found, the direction is 
consistent: younger age, non-white race/ethnicity, lower income, lower literacy and unstable 
housing are usually associated with non-adherence in developed countries (Meyer & 
Ogunbanjo, 2006; Machtinger & Bangsberg, 2006).  Heyer and Ogunbanjo (2006) found 
adherence among older persons to be better. 
 
2.10.6.1  Attitude and Beliefs 
A  person’s  knowledge  and  beliefs  about  HIV  and ART can influence adherence.  People 
who  understand the relationship between adherence and viral load, and between viral load 
and HIV disease progression, are more likely to be adherent than people who do not 
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understand this relationship.  Adherence is likely to be enhanced in people who strongly 
belief in the efficacy of ART (WHO, 2003). Beliefs about ART such as issues of toxicity and 
adverse side effects may negatively affect adherence (WHO, 2003).  Friedland and Williams 
(1997) report that studies in reference to AZT revealed that non adherence was influenced by 
the lack of belief in the efficacy of AZT and fear of its side effects. 
 
Pratt (2003) asserts that a most important factor in adherence to HAART is the person’s 
health beliefs and experiences in relation to medication and HIV disease. Pratt further states 
that there is good quality evidence to demonstrate that many HIV infected people understand 
the seriousness of their illness, recognise the importance of adherence and are aware of the 
virological consequences of poor adherence and that these factors increase the likeliness of 
optimal adherence. A positive outlook or optimistic approach to life combined with perceived 
control over personal health also appears to benefit adherence to HAART (Pratt, 2003).   In 
general, persons who understand the goals of antiretroviral therapy are more likely to adhere 
as required (Friedland & Williams, 1997; Pratt, 2003). 
 
A new and significant finding from a qualitative South African workplace study which 
examined barriers to and facilitators of adherence by Dahab et al. (2008) was denial about the 
existence of HIV disease and denial about a HIV positive diagnosis.  According to this study 
persons with this belief will not take their treatment because they do not believe that HIV is 
the cause of their illness; they believe they were bewitched and that the HIV virus has 
nothing to do with their illness.  A health care provider explained that a person who did not 
think that HIV existed or that he was infected reported that he stopped taking prescribed ART 
because he did not feel that this medication was necessary. 
 
The Dahab et al. (2008) study purposively sampled a small group of individuals and was 
designed to identify potential barriers to and facilitators of adherence in a workplace setting 
and may not be generalisable. However, complementing person in need of treatment 
information, with health care provider information using in-depth interviews enabled greater 
insight into the complexities of adherence behaviour. There appeared to be greater 
congruency between factors explained by HIV positive persons and health care providers 
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(Dahab et al., 2008).  This study clearly demonstrates the depth of information that can 
emerge when listening to the individuals experiences of adherence.  
 
2.10.6.2  Motivation 
A person’s motivation to adhere as prescribed is influenced by the value the person places on 
treatment and the confidence he or she has to follow instructions as indicated.  A person on 
treatment may choose to adhere or not to adhere based on his or her understanding of the 
risks and benefits of the prescribed treatment regimen (cost-benefit ratio), (Friedland & 
Williams, 1997; WHO, 2003). When a person on treatment shows a decrease in viral load and 
an increase in CD4 count their trust in the efficacy of treatment increases.  As trust and belief 
can change over time, it is important to discuss this theme during every follow-up visit.  
When the value of treatment for a person’s daily functioning is pointed out during routine 
check-ups, motivation is enhanced (Vervoort et al., 2007). 
 
2.10.6.3  Knowledge and Understanding 
Pratt (2003) asserts that the person on treatments ability to make decisions and participate in 
discussions concerning treatment is central to achieving good patterns of adherence. This 
happens because persons who are well-informed are more likely to be adherent because they 
understand the reasoning behind treatment and the consequences of poor adherence. Vervoort 
et al. (2007) state that persons on treatment should receive information about their medication 
that is appropriate to their level of understanding. In this way individuals will receive 
information that will guide them towards behaviours that constitute good adherence practice.  
In order to negate the possibility of faulty personal interpretations of adherence it is important 
to ask a person on treatment to describe their understanding of good adherence behaviour 
(Vervoort et al., 2007).  Pratt (2003) states that even the most knowledgeable and well-
informed person may forget to take a particular dose or make an informed decision to miss a 
particular dose.  
 
2.10.6.4  Social Support 
Social support for adherence is defined as encouragement from family and friends for the 
person on ART to take their medication exactly as prescribed by their health care professional 
(DiMatteo, in Kajee 2008).  Social support in HIV infection may also be described as the 
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assistance offered to HIV positive persons by their social network as opposed to a 
professional, and is often associated with better health outcomes (Ncama et al., 2008).  
Williams and Friedland (1997) state that adherence rates are increased by significant others 
who understand the need to follow the regimen as they may help to organise the pill taking 
thus ensuring stringent adherence.   Persons who enjoy the privilege of supportive friends and 
families appear to adhere more stringently to their regimen than those without support. 
Persons on treatment are encouraged to involve family and friends in their care and are also 
encouraged to join support groups (Friedland & Williams, 1997; WHO, 2003). Social support 
also acts as a buffer to many psychological problems and therefore positively influences 
adherence behaviour.  The presence of stable relationships and having access to social and 
emotional support increases the likelihood of optimal adherence.  People who live alone and 
who have poor social networks are less likely to be adherent (Pratt, 2003).  The absence of a 
supportive social environment and fear of stigmatisation are generally associated with non-
adherence (Heyer & Ogunbanjo, 2006). The fear of stigma and being seen taking ART by 
those outside of the persons close social networks present a significant barrier to normalizing 
adherence behaviour (Pratt, 2003). 
 
Social support is a critical aspect of living with chronic conditions such as HIV/AIDS  
because social support may improve the quality of life of persons affected by chronic diseases 
(Dahab et al., 2008; Gilbert & Walker, 2009 and Ncama et al., 2008). 
 
2.10.6.5  HIV Stigma, Discrimination and Disclosure 
 HIV/AIDS related stigma and discrimination refers to the prejudice, negative attitudes, abuse 
and ill-treatment that HIV positive people are subjected to just because of their HIV status.  
HIV positive people may be shunned by their family, friends and the wider community and 
they may experience poor treatment by the health care providers. These negative experiences 
may prevent people from accessing testing and treatment.  The UN Secretary General Ban 
Ki-Moon asserts: “Stigma remains the single most important barrier to public action. It is a 
main reason why too many people are afraid to see a doctor to determine whether they have 
the disease, or to seek treatment if so. It helps make AIDS the silent killer, because people 
fear the social disgrace of speaking about it, or taking easily available precautions. Stigma is 
a chief reason why the AIDS epidemic continues to devastate societies around the world.” 
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(Ki-Moon, 6 August 2008). 
 
The most important reported factors to negatively influence adherence  in Sub-Saharan Africa 
are cost, not disclosing HIV status to a loved one, fear of being stigmatised, followed by 
alcohol abuse and difficulty with complex regimens (Mills, Nachega, Buchan et al., 2006). 
Mills, Nachega, Buchan et al. (2006) further  state that their findings are supported by studies 
that have shown that the majority of persons on treatment have disclosed their HIV status to 
close family or friends and this has positively influenced adherence to ART.  Individuals who 
have not disclosed are more prone to treatment interruptions because their medication must 
be hidden and not taken in the presence of others (Mills, Nachega, Buchan et al., 2006; 
Naidoo, 2009). Disclosure may lead to negative comments from others and this may have an 
adverse effect on adherence. Persons prescribed ART are encouraged to bring along a 
treatment partner for support while they are adjusting to taking ART.  A treatment partner is a 
requirement for ART access in the public sector ART programme.  Openness about HIV 
status is encouraged as openness appears to positively influence medication adherence 
(Vervoort et al., 2007).   
 
Inungu and Karl (2006) assert that stigma is of utmost concern because it is both the cause 
and effect of secrecy and denial.  Secrecy and denial may cause people with symptoms of 
HIV infection to claim that they suffer from less stigmatised diseases such as cancer, thus 
preventing them from accessing life saving ART (Inungu & Karl, 2006). Aspeling and van 
Wyk (2008) also found that HIV stigma and fear of discrimination prevents persons from 
seeking treatment and admitting their status as they are terrified of being ostracised, ridiculed, 
or treated differently if their status is known. They may also have to deal with fear, rejection, 
shame, isolation, and disgrace, (Avert. HIV & AIDS Stigma and discrimination, undated). 
Women with HIV infection feel that HIV stigmatises them as unworthy and immoral and this 
may prevent them from seeking medical intervention (Aspeling & van Wyk, 2008). 
 
2.10.6.6  Self Efficacy 
 Heyer and Ogunbanjo (2006) explain self-efficacy as a person’s belief in his or her ability to 
take their medication as prescribed. WHO (2003) adds to the explanation and describes self 
efficacy as the confidence an individual has in their ability to manage their condition.  Self 
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efficacy is therefore most likely to be positively associated with medication adherence and 
people who view taking medication as a process that requires much effort are more likely to 
be non-adherent (Heyer & Ogunbanjo, 2006). 
 
2.10.6.7  Psychological issues 
Untreated  depression  and stress are strong  predictors of  non-adherence because  feelings of 
hopelessness are associated with the loss of will to care for the self (Amberbir et al., 2008; 
Heyer & Ogunbanjo, 2006; Mills, Nachega, Buchan et al., 2006; WHO, 2003).  Depressed 
mood and mental health problems have consistently been associated with poor adherence to 
HAART as symptoms of depression such as lack of motivation, poor organisation and 
difficulty in remembering and concentrating make adherence an extremely difficult task 
(Pratt, 2003). WHO (2003) and Pratt (2003) could find no conclusive evidence to link 
substance abuse to non-adherence. Substance abuse or alcohol misuse are associated with 
non-adherence because indulging in this kind of behaviour may interfere with a person’s 
ability to cope with taking the complex HAART regimens as optimal lifelong adherence 
requires a certain high level of  organisation.  Pratt (2003) asserts that difficulties with 
adherence may be associated with the chaotic lifestyle of people who abuse drugs and alcohol 
rather than the substance abuse.  Frank and Duncan (2009) state that alcohol and drug abuse 
are more likely to affect a person’s ability to remember to take their medication and so 
negatively influence adherence. Substance abuse may lead to sexually risky practices and 
health compromising behaviour which may include poor adherence (Frank & Duncan, 2009). 
Co-morbidities such as depression, drug and alcohol abuse and certain cancers, for example, 
may contribute significantly to poor adherence behaviour (Pratt, 2003; WHO, 2003; 
Machtinger & Bangsberg, 2006). 
 
The person’s views on illness and health and his or her level of belief in the effectiveness of 
the medication are predictive of adherence and therefore a person may choose adherence or 
non adherence based on his or her understanding of the risks and benefits of the 






2.10.6.8  Parenthood and Responsibility 
Aspeling and van Wyk (2008) found that the responsibility of parenthood and the desire to 
raise one’s own children were huge motivating factors. This study found that children have a 
positive influence on adherence because parents were determined to raise their children and 
taking  ART  meant that they could achieve their goal.  Adherence behaviour was  reinforced 
because children often reminded their parents to take their medication (Aspeling & van Wyk, 
2008). According to Aspeling and van Wyk (2008) this finding differs from the literature 
which  identifies  caretaking  responsibilities  as  interfering   with   adherence  or  negatively  
influencing adherence. 
 
2.10.6.9  Religion and Spirituality 
Aspeling and van Wyk (2008) also found that religion indirectly facilitated acceptance of 
HIV.  Studies support the role of religion and spirituality in achieving hope and physical 
well-being among person living with HIV.  Hope contributes to the necessary lifestyle 
adjustment essential for good adherence (Aspeling & van Wyk, 2008). 
 
The Konkle-Parker, Erlen and Dubbert’s (2008) study on barriers and facilitators to 
adherence found that prayer and spirituality were considered important support for adherence. 
Participants in this study described prayer as the ability to trust God to help them through 
difficulties they may experience.  Prayer and spirituality were considered to be a source of 
internal support during times of distress (Konkle-Parker et al., 2008).  
 
2.10.6.10  Culture and Traditional Medicine 
Traditional medicine claims to cure HIV whereas ART halts the progression of HIV disease.  
Aspeling and van Wyk (2008) found that even though no participant reported taking 
traditional medicine, some believed that traditional medicine can cure HIV disease.   The 
consequence of this belief is that some people may combine traditional medicine with ART 
thereby causing sub optimal drug levels of lifesaving medication (Aspeling & van Wyk, 
2008).  The Dahab et al. (2008) workplace study reported that both persons and health care 
providers agreed that ART and traditional medicine should not be taken at the same time.  
The consequences of this belief was that some persons reported that they stopped ARV 




The belief that persons on treatment are solely responsible for taking their treatment reflects a 
misunderstanding of how the various factors impact upon a person and so affect a person’s 
behaviour and capacity to adhere to their treatment as prescribed. 
 
2.11  Conclusion 
Conway (2007) asserts that success with any pharmacological intervention depends not only 
on the intrinsic properties of the prescribed medication but on the individual’s ability to take 
the medication reliably. ART requires therapeutic adherence rates of greater than 95% for 
optimal clinical benefit.  An individual’s ability to take medication may be influenced by 
many factors that may impede or facilitate medication adherence.  Interventions that address 
barriers to adherence in a specific way, and those that support facilitators of adherence, may 
be key to the long-term success of ART, in a given person (Conway, 2007).   In doing so the 
potentially dangerous situation of drug resistance which may compromise ART programmes 
and future options as well as the life threatening consequences of non-adherence may be 
avoided.  Optimal adherence also ensures less susceptibility to opportunistic infections such 
as TB and pneumococcal infections because of a functional immune system characterised by 
high CD4 cell counts and negligible viral load.  Undetectable viral load or negligible viral 
load has an added benefit of making such a person less infectious thus a positive factor in 
HIV prevention. 
 
Studies such as Dahab et al. (2008),  Aspeling & Van Wyk (2008) and Konkle-Parker et al. 
(2008) demonstrate how culturally relevant and novel findings may emerge when using 
qualitative methods to better understand factors that influence adherence to antiretroviral 
medication.  These findings may be significant to specific populations as the necessary 
interventions to improve adherence will take into consideration the issues experienced by this 
population of people.  
 
Van Dyk (2005) asserts that strategies to improve adherence to antiretroviral medication and 
the development of effective but person friendly regimens are much needed.  In developed 
countries, resources are readily available to HIV health care providers and their clients, and 
resources include printed material, electronic media, websites, SMS messages, support 
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groups, electronic pill counters and alarm beepers, amongst others.  Resources may not be 
easily accessible everywhere in Africa and it might be important for people in developing and 
underdeveloped countries to find their own unique ways of positively influencing adherence 
to antiretroviral therapy.  When developing adherence programmes, it is important to take 
into account factors that are specific to the developing or underdeveloped country. Cultural 
perceptions of what causes HIV; attitudes to health and sickness; a culture of non-disclosure 
that means no community support for the person; stigmatisation; illiteracy; differing concepts 
of time; practical and financial constraints involved in getting to clinics and lack of health 
care providers in the public service to discuss treatment issues are examples of some factors 
that might influence the ability of a person to adhere optimally (Van Dyk, 2005). 
 
All of the above-mentioned factors may interact and affect a person’s capacity to adhere to 
treatment. Non-adherence should therefore not be viewed as an isolated single factor 
problem, but rather as a multi-dimensional problem.  The ability of persons on ART to adhere 
optimally is likely to be compromised by more than one factor, and health care providers 
need to work with persons to assess all potential factors systematically.  All five dimensions 
need exploration that will lead to a deeper understanding of the factors that influence 
adherence. 
 
Mills, Nachega, Bangsberg et al. (2006) state that there is a paucity of qualitative research in 
developing countries. This is paradoxical as most developing countries are experiencing 
HIV/AIDS epidemics with South Africa recording the highest number of HIV positive people 
in the world.  This study hopes to demonstrate the value of the qualitative approach in order 
to better understand the factors that influence  HAART adherence. 
 
Improving adherence is arguably the single most important potentially alterable means of 








Chapter 3:  Research Methodology 
 
3.1  Rationale for choosing the Qualitative Approach 
According to Reid and Smith (in De Vos, Strydom, Fouche & Delport, 2005) the qualitative 
approach enables a researcher to gain first-hand, holistic understanding of phenomena of 
interest by means of a flexible strategy of problem formulation and data collection. 
Understanding phenomena involves aims that generally seek answers to questions about the 
‘what’, ‘how’, or ‘why’ of phenomena and this is characteristic of the qualitative approach, 
rather than ‘how many’, or ‘how much’ (Green & Thorogood, 2004). 
 
Persons in need of treatment are unique, and it is these unique, subjective experiences of what 
influences adherence that is of vital importance for our understanding of adherence.  In order 
to better comprehend these experiences it was important that the researcher make sense of the 
participant’s world in order to see how they perceive their situation, to understand what their 
situation means to them and to relate this to life-saving decisions that will always be an 
integral part of their daily existence (Green & Thorogood, 2004; Neuman, 1997).   
 
This study may provide insight and justification that there is no one fit for all; but that each 
population of people are unique and that their subjective experiences is crucial in order to 
understand adherence behaviour and the factors that influence adherence behaviour. 
 
This research is therefore a qualitative descriptive study to explore the factors that influence 
HAART adherence among persons who access treatment in the greater Durban area. This 
qualitative study attempts to better understand phenomena, the ‘what’, ‘how’ or ‘why’ 
questions that relate to factors that influence adherence to life-saving medication (Green & 
Thorogood, 2004). 
 
3.2  Sampling Technique 
Glass and Strauss, (in Green & Thorogood, 2004) argue that the strength of the grounded 
theory approach  lies in the cyclical process of collecting  data, analysing it, developing a 
provisional coding scheme and using this to influence further sampling until saturation is 
reached. The non-probability theoretical sampling technique was therefore a method of 
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choice for this study.  This technique afforded the emergence of a rich dense account of the 
factors that influence adherence from the data collected (Green & Thorogood, 2004).  This 
sampling technique may also be described as a particular kind of purposive sampling as the 
sample was selected on the basis of their ability to contribute to the development of 
theoretical constructs (Ritchie & Lewis, 2003). 
 
3.3  Sample, Sample Size and Sampling Criteria 
The researcher must emphasize that despite the fact that KZN has the most people on ART in 
the country, it was no easy task to find people on ART willing and eager to share their 
knowledge of what influences adherence with the researcher.  It was challenging and 
frustrating at times even though the researcher networked with many people who interacted 
with persons on ART during her post graduate studies in HIV/AIDS Clinical Management at 
the University of KwaZulu-Natal in 2007 and 2008. The researcher realised that an approach 
that demonstrated an understanding of confidentiality and trust issues in HIV/AIDS research 
was most necessary for colleagues to commit to identifying potential participants who would 
fit the sample criteria. Patience and perseverance eventually paid off as colleagues identified 
and helped recruit the small sample of thirteen people.  
 
HIV infection is still highly stigmatised and persons infected and affected can be described as 
a vulnerable population. Because of the stigma and discrimination associated with a HIV 
positive status, eligible participants recruited for this study were only those who were willing 
an eager to share their experiences with the researcher.  The researcher anticipated difficulty 
in the recruitment of the sample but felt that finding a small sample would be achievable. 
 
The sample was identified by social workers and health care professionals working in the 
HIV/AIDS field. Potential participants were referred to the researcher with the consent of the 
participants.  Eligible participants recruited were persons older than twenty one years of age 
who have been on HAART for at least two years, and who appear to be adhering successfully 
to therapy.  Language criteria specified the need for participants to be able to communicate 
with reasonable proficiency in English.  A small sample of thirteen participants, were eager 
and willing to share their experiences for the purposes of this study. The sample was selected 
on the basis of their ability to contribute meaningfully to understanding the factors that 
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influence adherence to antiretroviral medication. This small sample size proved to be 
sufficient to elicit the kind of data necessary for a meaningful short dissertation.  
 
Eight participants were female and five were male. The male participants accessed 
antiretroviral therapy from their workplace wellness programme and the female participants 
accessed treatment either using private, semi private or public health care. Three female 
participants accessed private health care, one semi- private health care, and four accessed 
public health care in the greater Durban metropolis.   
 
3.4  Data Collection Method 
DeVos et al. (2005) state that interviewing is the predominant mode of data collection in 
qualitative research.  Kwale (in De Vos et al., 2005:292) defines the qualitative interview as 
“attempts to understand the world from the participants point of view, to unfold the meaning 
of peoples experiences and to uncover their lived world prior to scientific explanations”. 
 
The in-depth interview was the data collection method of choice for this study.  This was 
appropriate because in-depth interviews combine structure with flexibility, is interactive in 
nature and allows the researcher to use a range of questions to further explore and clarify 
responses. In this way the researcher listens to the subjective experiences of participants and 
is able to gain a deeper understanding and insight  into the factors that influence adherence to 
antiretroviral therapy (Green & Thorogood, 2004; Ritchie & Lewis, 2003).   
 
3.5  Data Collection 
Interviews were conducted from August 2009 to February 2010.  In-depth interviews of one 
to one and a half hours were conducted in English with each participant.  The preferred 
method of data collection was tape-recording combined with detailed handwritten note 
taking.  Regarding note taking, the researcher was particularly vigilant and careful to ensure 
that the written word was what the participant intended to state. The researcher would 
rephrase a response or repeat a question in order to ensure that the written record was the 
participants response to the question asked.  This measure helped to verify the note-taking 
process. Of the thirteen interviews, one participant preferred not to be recorded and the 
researcher experienced tape recording problems during the workplace interview sessions 
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which resulted in two clear recordings, one half recording and two interviews relied only on 
detailed note taking.  
 
The researcher used an interview guide.  Below are the questions that were formulated to 
guide the process of interaction between researcher and participant: 
 
• I would like to hear your story about being HIV positive and being on treatment.  I am 
particularly interested in what helps you to remain on treatment. 
• What was it like, how did you react on learning about being HIV positive? 
• What was it like when you first started taking your medication? [detailed exploration, 
for example, at what point was the decision taken to take medication, what hopes, 
fears, concern did you experience, who was around to support you, what was the 
initial reactions of health personnel like towards you?] 
• “What makes it harder for you to take your HIV medication regularly?” (Konkle-
Parker et al., 2008) [In-depth exploration of factors identified in the key questions]. 
• “What makes it easier for you to take your HIV medication regularly?” Konkle-Parker 
et al., 2008) [in-depth exploration of factors identified in the key questions] 
• What is it like now that you are on medication for quite some time? 
• If there is anything else that would help you to take your medication as required what 
would this be? 
• What do you think will help other persons on ART to take their medication as 
required? 
• What do you think makes it difficult for people on ART to take their medication as 
required? 
 
Two female participants were eager to share their stories and expressed their feelings of relief 
and comfort for the opportunity to talk about their experiences of living with HIV.  The 
interview sessions appeared to be cathartic for these participants and the researcher gave 
these participants the opportunity to talk as it was important for the researcher to meet the 




The other participants were allocated time off from their work schedules but were assured by 
their employers that it would be alright if the interviews went on for slightly longer than 
expected.  The researcher found that all the participants had enough time to answer the 
questions that was used to guide the interview. The tape recording was transcribed verbatim 
in preparation for analysis of data.  The detailed hand written account of what transpired 
during the interview was also available for analysis. The process of sampling and 
interviewing continued until the researcher was satisfied that data saturation took place, in 
other words, no new insights emerged (Denzin & Lincoln, 2000; Ritchie & Lewis, 2003). 
 
3.6  Data Analysis 
Data was analysed using a thematic content analysis approach. This involves analysis of the 
data to identify recurrent or common themes and to categorize information under identified 
themes that emerged from the data. Transcripts were perused on a line by line basis to 
identify phrases that could be assigned to categories or themes and a ‘scissors and paste’ 
method was used to place the identified themes into their categories (Dahab et al., 2008; 
Green & Thorogood, 2004).  Phrases were colour coded to ensure that they were placed 
under the correct categories. Overlap of themes was expected as definitions of constructs may 
differ slightly according to different authors.  For example, social support may be categorised 
under socioeconomic factors or person factors. When overlap occurred the researcher made 
the reader aware of where that particular theme would be discussed in order to avoid 
repetition.  The categories or themes that emerged from the data are identified and explored 
in Chapter 4. The factors that emerged were compared to what was found in the literature to 
ascertain commonalities and differences and to see if any novel factors emerged that could be 
of significance to the individual, this community of participants, their health care providers 
and the systems that influence their health outcomes. 
 
3.7  Ethical Considerations 
Social research in many instances involves an intrusion into people’s lives and may depend 
on building a relationship of trust with the participants so that information that they might not 
ordinarily wish to make public is revealed under certain conditions only.  Ethical 
responsibility is therefore essential at all stages of the research process and must be seen as an 
integral part of the whole process (Miller & Brewer, 2003). The sensitivity of this research 
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must be appreciated; therefore the researcher exercised great caution in ensuring that 
informed voluntary consent and confidentiality was fully discussed with each participant. 
Ethical clearance for this study was granted by the University of KwaZulu-Natal ethics 
committee. 
 
3.7.1  No Harm To Participants 
It was important to ensure that the research posed no potential harm to the participants and 
plans for further counselling were put in place for participants to access if they felt the need 
for support after the interviewing process. 
 
3.7.2  Informed Consent 
Informed consent ensured that the purpose of the research, potential benefits and risks, and 
any additional information that the participants and researcher deemed necessary was made 
available to each participant to enable the process of informed decision making about their 
participation in this study. The researcher made sure that each participant was given the 
opportunity to listen to her request for their participation in this study and to ask any 
questions that they may have concerning the research project. All participants were fully 
informed of the rationale behind the research and the rationale for their inclusion in the 
project. Participants were given an informed consent document to sign; to verify that all 
aspects of the research were clearly discussed with each participant. Participants were assured 
that they could withdraw at any stage of the process if they felt uncomfortable or experienced 
any doubt or discomfort. 
 
3.7.3  Confidentiality  
Due to the stigma and associated discrimination often experienced by HIV positive people it 
was important to conceal the identities of the participants. Participant’s names were therefore 
changed in order to protect their identities. What was meant by confidentiality was discussed 
with each participant and participants were made aware of the supervision process and about 
what would be revealed during this process. The research report was also discussed and 
participants were assured of their anonymity in any written documents. Pseudonyms are used 
in the reporting of data.  The researcher worked sincerely on developing a relationship of 
trust with each participant so that they could feel safe enough to share their experiences with 
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the researcher.  This relationship may have added depth to the quality of responses that the 
researcher elicited from the participants. 
 
3.8  Issues Concerning Reliability and Validity in Qualitative Research 
Bashir,  Afzal and Azeem (2008) state that reliability and validity are conceptualised as 
trustworthiness, rigor and quality in the qualitative approach and may be achieved by 
eliminating bias and increasing the researchers truthfulness of their assertions about some 
phenomena, by using,  for example, triangulation.  McMillan and Schumacher, (in Bashir, 
Afzal and Azeem, 2008) suggest that researchers use a combination of strategies from a list 
of strategies they recommend, to increase validity in the qualitative research paradigm.  The 
list of strategies include:  prolonged and persistent  fieldwork; multi-method strategies; 
participant language verbatim accounts; low-inference descriptors; multiple researchers; 
mechanically coded data; participant researcher; member checking; participant  review; 
negative or discrepant data. 
 
The researcher used a tape recorder as well as detailed hand written notes of the interviews.  
During the process the participants were often asked to rephrase or clarify in order to ensure 
that the intended message was recorded, both mechanically and by hand.  The researcher 
often reflected her understanding of what was said to the participants, for their input, in order 
to ensure that the intended message was recorded for purposes of analysis. Transcripts of 
interviews were done immediately after the interviews as most of what transpired during the 
interview was still fresh in the mind of the researcher. The recordings were listened to more 
than once to ensure that the verbatim transcripts were accurate and of a high quality.  
Verbatim recording ensured that participant’s perceptions were recorded. When recording 
failed, the researcher would read her recording of participant responses to the participant, to 
ensure that the participants perceptions were correctly recorded. 
 
The researcher also made notes on her feelings regarding the research,  her interaction with 
the participants and anything personal that may influence her ability to commit fully to the 
process of interviewing or collecting data.  Being self aware possibly enhanced the quality of 




3.9  Limitations of this Study 
The intention of this study was to listen to the individual’s experience of their treatment and 
to gather rich and in-depth information about their experiences of treatment adherence rather 
than to generalise the findings to the larger ART population.  The sampling method and small 
sample size means that the results of this study may not be applicable to all persons who 
access ART.  
 
HIV/AIDS is still a highly stigmatised potentially life threatening disease. For this reason the 
researcher sought only good adherers who were willing and eager to share their stories about 
their treatment adherence with her.  This may be limiting as barriers to adherence would 
emerge from the frame of reference of individuals who appear to be adhering optimally.  In 
order to minimize possible respondent bias the researcher put extra effort into explaining the 
importance of honest answers to questions posed taking into consideration the seriousness of 
the HIV/AIDS pandemic in South Africa.  Participants were made aware of the importance of 
their answers and of the contribution they were making to improve strategies for optimal 
adherence to prescribed medication.  Possible research bias was minimized by ensuring that 
no leading questions were posed and by assessing and evaluating what went on during each 
interview and making the necessary changes to improve the quality of the data that emerged. 
This self awareness and constructive criticism of the process made the researcher feel 
confident that everything possible was put in place to ensure that bias was minimized.  The 
researcher therefore felt that the research findings were valid and reliable in this setting. 
 












Chapter 4:  Results 
 
Green and Thorogood (2004) explain that the most basic type of qualitative analysis is an 
analysis of the content of the data to identify the recurrent or common themes.  The interview 
transcripts were analysed and colour coded according to the themes that emerged from the 
data.  Green and Thorogood (2004) explain that the easiest way to do this kind of analysis is 
using the ‘scissors and paste’ method.  The researcher preferred to colour code transcripts and 
then place them under identified themes or categories for analysis. 
 
Data was tabulated in order ensure that all the information gathered was accounted for and to 
make analysis of the data more user friendly. The tape recorded interviews allowed the 
researcher to produce direct quotes as well as record data in the third person and when the 
researcher relied only on hand written notes then the data was recorded in the third person 
only.  A wide range of factors that may influence adherence emerged from the responses.  In 
certain instances main categories were better explained according to subcategories.  
 
Participant information in presented in the tables below.  The researcher refers to these tables 
in the discussion of results. 
 
Table 4A:  Participant Demographics 
Participant Information Collected from August 2009 to Jan 2010   














0 public 1999 2006 




1 private 2007 2007 
 
3 Joyce female 35 Housekeeper married 
 
3 public 2006 2006 








5 Trace female 35 Receptionist single 
 
3 public 2005 2005 




2 private 2006 2007 




private 2006 2007 
 
8 Nosi female 31 Receptionist single 
 
1 private 1999 2002 
 
9 Kay male 36 Artisan married 
 
1 workplace 2006 2006 
 
10 Bob male 43 Artisan married 
 
2 workplace 1997 2005 
 
11 Andy male 35 Artisan married 
 
2 workplace 2003 2003 




5 workplace 2004 2004 




4 workplace 2003 2003 
 
Table 4B:  ART regimen, years on treatment, CD4 count at diagnosis and current and 










CD4  HIV Testing 
1 Mel 3 3TC+AZT+NVP 400 196 600 private doctor 
 
2 Sharon 2 (TNF+FTC) + EFV 78 78 279 hospital 
 
3 Joyce 3 3TC+d4T+EFV   <200 <200 >350 PMTCT 
 
4 Futi 5 3TC+d4T+EFV  100 100 >400 
staff 
programme 





6 Wini 2 3TC+AZT+EFV 400 20 300 VCT 
 
7 Thoks 2 3TC+AZT+EFV   >200 110 >350 VCT 
 
8 Nosi 7 (3TC+AZT)+EFV 552 265 1500 private doctor 
 
9 Kay 3 (3TC+AZT)+EFV <100 <100 >400 Wellness 
 
10 Bob 4 ABC+ddI+LPV/RTV 
      
 <100 <100 897 Wellness 
 
11 Andy 6 (3TC+AZT)+EFV   <100 <100 >400 Wellness 
 
12 Frank 5 (3TC+AZT)+EFV 
      
  <100 <100 >400 Wellness 
 
13 Kamy 6 ABC+ddI+LPV/RTV 133 133 >400 Wellness 
 
4.1  Social Support 
All the participants reported having access to social and emotional support from family, 
friends or colleagues for adherence to their medication and all the participants shared that 
having such support contributed significantly to their adherence behaviour. The married 
participants expressed the value of supportive spousal relationships that encouraged 
adherence, especially if their spouses were HIV positive and on treatment.  The single 
participants also benefited from close relationships with people they could trust to support 
them to maintain their adherence behaviours. One participant shared about the value of 
support groups in making her see how well people on ARVs do and that she is not alone.  
Two participants shared that they would like to be part a support group because sharing 
experiences and being with other HIV positive people is likely to be empowering. Most of the 
participants shared that their health care providers were very supportive, providing social as 
well as treatment support.  Participants on the wellness programme and those who accessed 
private and semi-private health care were particularly expressive about the wonderfully 
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supportive relationship they shared with their health care providers. These findings are 
consistent with the literature on social support which states that the presence of stable 
relationships and having access to social and emotional support will positively influence 
adherence behaviour (Amberbir et al., 2008; Dahab et al., 2008; Heyer & Ogunbanjo, 2006; 
Pratt, 2003; WHO, 2003). 
 
Below are extracted quotes and responses that demonstrate the value of social support in the 




Mel “You don’t have to tell the world but you need to tell at least one person, 
everyone I know is my support, Mom Dad, friends, cousins” 
Sharon 
 
“I know I need support ... talking to people does help ... I can talk to my 
attorney friend, my human resources manager at work and my doctors, and 
discovery (her medical aid), has a direct line to counsellors I can talk to”.  
“It’s good to have a support group ... if you see me there and see how good I 
am doing and you can’t believe that I am HIV positive  unless I tell you ... this 
is empowering because I will want to take my medicine just like her to look so 
good”.  
Joyce Joyce shared that she receives wonderful support from her employers and their 
family; her husband, mother, daughter, a friend and she has her own 
counsellor who comes to visit every month.  Joyce also shared that she found 
group counselling particularly helpful because she realised that she is not 
alone and she could see how well people get when they are on ARVs. 
Futhi  Futhi received support from her sister and her employer. 
Trace 
 
Trace shared that she received wonderful support from the HIV counsellor at 
her workplace. 
Wini “I have a lot of family support, that is why I don’t forget to take my treatment,  
when I was sick last year my mom came to stay with us, just to support me 
because she was worried about me”. Wini felt that support from family 
especially the people who live with you is most important to people on ARVs.  
She has the support of her husband and her family, especially her mother who 
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came to nurse her back to health when she took ill. She also has supportive 
health care providers. 
Thoks Thoks expressed that she receives lots of care and support from her family and 
this includes her mom, four brothers and two sisters. Her employer and the 
HIV counsellor at work are also very supportive. “My family, my kids make 
me take my meds ...when it is time to take my meds ...they help me ...make a 
joke to make me take my meds ... say ... it’s tablet time ....if I am tired my mom 
will sit next to me to make me take it”. 
Nosi Nosi shared that everyone she surrounds herself with is very supportive of her 
status. She gets lots of support from her family, health care provider and 
employer. “You need a support system ...you can’t be on your own; you need 
people”.  “Everyone who supports you gives you hope”.  
Kay Kay has the support of his wife and the support of the wellness clinic staff 
which includes the nurses and the doctor. “I can open up to him ...talk man to 
man ...if doctor is not there I can go and sit down and talk to her 
(occupational health nurse)”. 
Bob Bob and his wife are HIV positive and they provide support for each other. 
They remind each other to take their meds. 
Andy Andy and his wife are HIV positive and they support each other.  His brother 
and sister know his status and are supportive. He felt that it is important to be 
honest with family, “family must know then they know how to live with me” 
He also receives “good close support” from the doctor and nurses at the 
wellness clinic at work.  
Frank Frank and his wife are on ART and they support each other, “me and wife take 
tablets at same time”. Frank’s sister and his older children are aware of their 
HIV positive status and they are fine with it, “wife and children told me to 
take it”.  He has the support of his family and his sister who is a nurse, and the 
staff at the wellness clinic at work. 
Kamy Kamy said that his wife keeps an eye on him and makes sure that he takes his 
pills. She will phone him to remind him to take his pills. They support each 
other.  Kamy would like to be part of a support group for he feels he has a lot 
of knowledge of HIV/AIDS that he could share. He wants to help others who 
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are HIV positive. 
 
4.2  Socio-economic Factors 
Within the broad rubric of socio-economic factors three subthemes emerged: the impact of 
poverty, transport costs and lack of child care. 
 
4.2.1  Poverty 
Two participants reported that some people default on treatment in order to keep their CD4 
count below 200 cells/mm³ in order to continue receiving the social grant for persons with a 
CD4 count less than 200 cells/mm³.  One participant shared that she was aware of people 
selling their stocrin (efavirenz) because of financial constraints because they needed money 
for their families. Another participant explained how unemployment may lead to depression, 
hopelessness and non adherence. These findings are supported in the literature as Kajee 
(2008) states that when social grants are associated with AIDS-related indicators such as CD4 
counts or viral load, then non-adherence may become an attractive option for persons who 
fear losing their grant because this is often the families only source of income.   
 
4.2.2  Transport Cost 
One participant shared that financial constraints may impact negatively on adherence 
behaviour because of the cost of transport to and from a clinic. This finding is supported by 
Ware et al. (2006).   The researchers explained that the cost of transport appears rather 
complex as it combines at least four factors such as  long distances to and from the clinic; 
actual cost, such as high rates of taxi fares; payment in cash and the cost of incurring these 
costs indefinitely because of regular clinic visits.  Kajee (2008) also found  that funds to 
travel to and from a ART clinic may not be available for many people  who need to attend 
clinics.  Tuller, Bangsberg, Senkungu, Ware, Emenyonu and Weiser (2009) found that 
transportation costs forced persons into having to make serious sacrifices in other essential 
areas just so that they could adhere to their treatment and this may not be sustainable, leading 
to suboptimal adherence behaviour. Kajee (2008) further states that competing  demands of 
many responsibilities such as work and family as well as the stresses associated with poverty 




4.2.3  Lack of Child Care 
One  participant highlighted the fact that needing  someone to look after your child may pose 
 as a barrier to adherence. This finding is supported by studies such as Kajee (2008) who 
found that persons on treatment need to attend clinics on a regular basis for routine checkups 
and to collect medication.  Persons on treatment may therefore need childcare support while 
they attend the clinic.   Child care is often not easily accessible for persons on treatment or 
child care may not be affordable,  and this may lead to persons missing clinic appointments 
for checkups or to collect medication.  Lack of child care  may therefore negatively influence 
adherence to ART. The El-Khatib, Ekstrom, Coovadia, Abrams, Petzold, Katzenstein, Morris 
and Kuhn (2011) study supports this finding as they found that providing care for children 
with an uncertain partner is often associated with reduced adherence and an increased need 
for social support.   
 
Selected participant responses that shed light on socio-economic hardships that may impact 
negatively on adherence behaviour are  tabulated below. 
Participant  
Mel “People also don’t adhere because they get the grant ... don’t adhere so their 
CD4 count goes down” ... also can make money, R500 for a bottle of 
stocrin”. “Financial constraints can make adherence difficult because you 
need ‘combi’ fare and someone to look after your child”.  
Nosi Nosi knows of cases where people go to collect their ARVs but then they 
stop taking their ARVs because they do not want to lose their social grant.  
Nosi expressed that eating healthy is expensive and most people can only 
afford potatoes and onions. 
Kamy Kamy explained that some people on ART “are unemployed and they get 
depressed because they have no work and they feel hopeless and this makes 
them forget to take their tablets”. 
 
4.3  Health Care Provider Factors   
Most of the participants shared  positive experiences about their relationship with their health 
care providers because they received social, emotional and treatment support for adherence 
from their health care providers.  Joyce was full of praise for the ART programme at St 
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Mary’s hospital which included information sessions, ART readiness sessions, counselling 
sessions, support groups as well as  counsellors who did home visits on a monthly basis.  The 
‘personal’ counsellor was always available to answer questions and to attend to any concerns 
regarding treatment and care during the home visits or telephonically.  Thoks explained that 
her interaction with the public health care system at Wentworth was not good as the staff 
were unpleasant towards persons in need of treatment.  She was not happy with the treatment 
she received and now attends McCords semi private hospital for her ART.  She was full of 
praise about the healthcare at  McCords which was affordable and supportive.  The staff were 
friendly, pleasant and easy to talk to.   
 
The public health care attendees were generally satisfied but were not very expressive about 
the relationship  between the health care provider and HIV positive persons, except for the St 
Mary’s attendee Joyce, and Mel who accessed treatment at Addington hospital. Mel shared 
that there are a few passionate doctors in the public sector as she experienced a passionate 
doctor when she first found out her status in hospital.  Mel explained that “the passionate 
doctor takes longer and shows he is concerned”.  She went on to explain that it is the attitude 
of the health care professionals that is important, “if I didn’t have people who were receptive 
to me I don’t know what I would have done”. 
 
The wellness clinic attendees and the participants who accessed private and semi private 
health care were full of praise, and spoke very highly of the encouragement and support, and 
the open and trusting relationship they shared with their health care providers. Kay, a 
wellness programme attendee shared, “I can open up with him, talk   man- to- man with him 
and he has an open door policy so his patients feel that there is always someone they can talk 
to if they need to”.  Health care providers at the wellness clinic took time to counsel attendees 
about anything that was troubling them regarding their treatment and their lives, “he explains 
things to me ... doctor counselled me and told me that drinking is bad with HIV meds”.  The 
doctor at the wellness clinic appeared to empathise with the persons on ART. He let the 
employees know that he acknowledged the difficulties associated with giving up, for 
example, alcohol.  He took time to listen and to counsel employees accordingly and to plan a 
way forward with the employees so that adherence would improve. In this study most of the 
participants experienced healthcare workers as caring,  trustworthy, open, friendly and easy 
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to talk to.  Health care service providers were also described as  good listeners who involved 
persons in treatment decisions. This finding was similar to the literature which states that 
health care providers who are sensitive to the persons needs and who develop an 
understanding of the persons situation were likely to facilitate adherence behaviour. The 
literature further states that persons who perceive their healthcare provider-person 
relationship as one of mutual respect and trust are more likely to be adherent because they are 
able to be open and honest about problems with adherence (Pratt, 2003; WHO, 2003; 
Williams & Friedland, 1998).  A supportive person- health care provider relationship is likely 
to enhance adherence and the qualities of the health care worker are an important factor in 
facilitating adherence (Williams and Friedland, 1998; Pratt, 2003; WHO, 2003). 
 
An area of grave concern mentioned by most of the participants was the lack of 
confidentiality with regard to HIV/AIDS treatment at most public clinics and hospitals.  Futhi 
and Thoks explained how confidentiality is compromised in the public health programme 
because everyone knows that if you are in “that queue” then you are waiting for ART.  Futhi 
stated that confidentiality for her is fine because she accesses her ART from the staff clinic 
and staff get special treatment.  She will never access her ART at the clinic near her home 
because then everyone would know her HIV status.  Bob explained that he lives in Tongaat 
but his wife attends the ART programme in Pietermaritzburg because if she goes to the clinic 
in Tongaat, then everyone will know her HIV status.  Frank shared a similar experience 
where his wife attends the HIV/AIDS clinic in Greytown because she is afraid that everyone 
will know her HIV status if she accesses ART in Tongaat, and the community will treat her 
differently if they know her HIV status.  The participants who accessed semi-private, private, 
and wellness programme healthcare  appear to have little concern about the confidentiality of 
their HIV status.   The wellness clinic participants were grateful for the fact that all 
employees attend the wellness clinic for a range of health related problems and collecting  
HIV medication was just one of the services offered.  There was no separate queue for  HIV 
positive persons. The wellness clinic participants were therefore full of praise for the care 
they received at their workplace wellness clinic. 
 
Issues about compromising confidentiality with regard to HIV status was not abundant in the  
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literature.  Sanjoba, Frich and Fretheim (2008) found that confidentiality at treatment centres, 
especially pharmacies was a concern because the pharmacy for dispensing ART was separate 
from the general pharmacy which made persons feel labelled by their health care facility.  
This is similar to what was experienced by persons collecting ART at public clinics or 
hospitals in Durban because of the separate queue for the collection of ART. Sanjobo et al. 
(2008) assert that this finding illustrates the importance of taking confidentiality and stigma 
issues into consideration when  provision of ART is being scaled up. Stigma and HIV is 
explained further under 4.6.2. 
 
Below are selected responses and quotes to give an idea of the participants experiences with 
regard to their health care service providers. 
Participant  
Mel “Passionate doctor takes longer and shows he or she is concerned”. “Attitude 
of health care professionals ...if I didn’t have people receptive to me I don’t 
know what I would have done”.  
“A problem because we sign for our meds ... People are seen going there ... 
you are in that queue then you have AIDS”. 
Sharon “My doctor says you are such a beautiful girl, you can get on with your life  
with HIV”.  Sharon has a trusting and good relationship with her doctors. She 
can phone them at any time if she if something is bothering her.  Her medical 
aid, Discovery also provide good service for their HIV patients; her 
medication is delivered to her home as an enclosed parcel so no one will know 
that it is HIV medication.  The Discovery counsellor phones her to provide 
support for her with her medication and she receives literature on HIV from 
her medical aid. 
Joyce Joyce stated that when she saw so many HIV positive people at St Mary’s 
looking so well she realised that she is not alone ... “not  only me with HIV”.  
The group counselling sessions were very supportive for Joyce because she 
did not feel so alone. Joyce shared that her doctors, nurses and counsellors 
explain everything to her very nicely and her hospital is the number one 
hospital to go to for ARVs.  
“St Mary’s ... good counselling ...you also get your own counsellor  ...he 
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comes once a month to visit at home...(Cowies Hill) St Mary’s is number 1 
hospital”. 
Futhi Futhi is happy with the treatment she receives on the staff programme at her 
workplace in a public hospital (Prince Mshiyeni). She is happy not to have to 
access treatment in the area where she lives (Umlazi) as then her status would 
be made public.  At her workplace everything is very discrete, “ARVs from 
staff programme...separate at Prince Mshiyeni ...no queues ....just get from 
staff sister, not fair that others have to sit in queues with others staring”. 
Futhi will not attend the clinic in the area where she lives because she will 
have to sit in the “HIV queue” to collect her ARVs and everyone will know 
her HIV status.  She is happy with the treatment she receives on the staff 
programme at her workplace as she does not have to sit in the “HIV queue” to 
collect her ARVs. 
Trace Trace received wonderful support and counselling from the hospice she was 
referred to when she was severely ill.  She was encouraged and supported at 
the hospice to take ART.  Since her recovery she is full of praise for the HIV 
counsellor and doctor at her place of work for the emotional and treatment 
support they provide for her. She gets her ARVs from Thembalabantu Clinic 
and has no complaints about the clinic. 
Wini Wini sees a HIV physician for her HIV treatment and a gynaecologist for her 
pregnancy.  She is confident about the care she is receiving in the private 
health care sector. 
Thoks Thoks was not impressed with the treatment she received at Wentworth 
hospital. She experienced the medical personnel as unpleasant in their attitude 
towards the ‘patients’ (health-care provider relationship).  Thoks is however 
full of praise about the treatment at McCords hospital (semi-private). Medical 
personnel were friendly and easy to talk to and they provide emotional and 
treatment support for her. Thoks explains that people are not eager to go to 
public hospitals for ARVs as they have to sit in the “ARV queue” and 
everyone comes to look to see who is in the HIV queue. 
Nosi Nosi spoke highly of her family doctor as he provides her with much support 
and encouragement and he spends time counselling her.  
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Kay  Kay spoke very highly of the wellness clinic and explained that the wellness 
clinic provides very good medication for the workers.  He spoke highly of the 
doctor, “ I can open up with him ...talk man-to-man with him and he has an 
open door policy so his patients feel that there is always someone they can 
talk to if they need to”. Kay felt that the wellness clinic is great because no-
one knows why you have come as people go there for all kinds of treatment. 
Kay trusts his health-care team to keep his HIV status confidential.  
Bob Bob trusts that the nurses and doctors at the wellness clinic can keep his HIV 
status confidential.  Bob explained that his doctor told him about a judge who 
is living for twenty years with HIV and he felt that this story gave him 
confidence that he too could take his medication and live a long and healthy 
life. Bob’s wife accesses her treatment in Pietermaritzburg as people don’t 
know her in that area.  She is unwilling to access ART where she lives 
because of the “ARV queue” and because fellow community members will 
treat her differently if they know her HIV status. 
Andy Andy has developed a close relationship with the doctor and nursing sisters at 
the wellness clinic at his workplace.  He further stated that “doctor talks to me 
.... he explains things to me ...doctor counselled me and told me that drinking 
is bad with HIV meds”. He is happy that co- workers come to the clinic for all 
their medical needs. 
Frank Frank expressed how the doctor and nurse at the wellness clinic explained to 
him about taking pills. His sister who is a nurse also explained. His doctor  
took time to explain about his drinking and how he must cut down and then 
eventually stop drinking because he is on ART. Frank also mentioned that the 
clinic is for anyone who is sick. Frank’s wife accesses treatment in Greytown 
because of confidentiality issues. If she accesses treatment at a clinic near her 
home, everyone will know her status.  Frank’s sister works at the hospital in 
Greytown and arranged for her to go there for treatment.  Frank also 
mentioned that the workplace clinic was for everyone. 
Kamy His doctor told him that if he takes his medication then everything will be fine. 
He listened to his doctor and everything is going well.  Kamy stated that all 
people in need of healthcare attend the same clinic. 
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4.4  HIV Disease Related Factors  
HIV disease related factors refer to those symptoms or infections that an individual may 
acquire or experience because of a weakening immune system response caused by HIV on 
the body’s defence cells. Most of the participants stated that they began to feel sick, tired, 
feverish or weak more often than not, or they experienced weight loss, or had a rash which 
could not be explained.  Seven of the thirteen participants were diagnosed with opportunistic 
infections. The list of opportunistic infections and symptoms experienced by participants  are 
presented in Table 4.4.A  Becoming susceptible to opportunistic infections, and unexplained 
illness, may be indicative of HIV infection and some degree of immune function 
deterioration.  Most of the participants discovered their HIV status when they were already 
immune-compromised at a CD4 cell count well below 200 cells/mm³.   Refer to Table 4B  for 
CD4 cell counts when diagnosed and current CD4 cell counts.  The above is in accordance 
with the literature which states that HIV infection in South Africa is often diagnosed late; 
when the CD4 cell count is well below 200 cells/mm³ and individuals with a compromised 
immune system are more likely to have advanced disease, present with opportunistic 
infections and have poorer health outcomes (AIDS2031, 2010; FHI & USAID, 2007 and 
Mahungu, Rodger & Johnson, 2009). 
 
Participant responses to indicate HIV disease related factors are presented below. 
Participant  
Mel Mel started getting sick almost every week for about two months.  Eventually 
her doctor requested an HIV test which came back positive. 
Sharon “I was very sick, my chest was heavy and they knew I suffered pneumonia but 
they didn’t know what was wrong with me”, Sharon was very ill with 
pneumonia.  She was in ICU because of the severe pneumonia (OI)). In 
hospital she discovered that the reason for her susceptibility to pneumonia 
was because she had untreated HIV infection which had severely depressed 
her immune response to infections. 
Futhi “ I was very thin, was very sick ... then got TB”, Futhi got very sick with TB 
and then found out that she had HIV (OI). 
Trace Trace shared that she was in denial of the HIV test result she received.  
During her pregnancy, she often got sick and her CD4 count dropped to very 
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low levels. She became very ill; so ill that her mother-in-law took her to the 
hospice. 
Wini  Even though Wini was diagnosed early, she experienced a very sudden drop 
in CD4 count this caused her to develop shingles (OI). 
Thoks “... got so sick ...Wentworth said I must come back for my appointment in Jan 
...was too sick ... went to McCords ... admitted to hospital ...put onto TB 
meds,  ...even got crypto” (cryptococcal meningitis).  Thoks shared that she 
battled to take her ARVs when she was sick. 
Nosi Nosi had a rash and fever for some time that wouldn’t get better with 
treatment. Nosi felt strongly that the stress she was going through made her 
susceptible to TB while she was on ARVs (OI).   
Kay “...actually, I was sick every day, I was feeling sick and weak all the time”. 
Bob Bob got very sick and had to be hospitalised.  He found out his status in 
hospital as his illness was due to HIV infection. “In 97, I was very sick ...had 
to go to hospital”. 
Andy “ish...got very sick ... with shingles ... doc explained to me ...said I must go 
for a HIV test ... get shingles ... worry about HIV!” 
Frank “started  to feel sick all the time ...got thin, weak, losing too much weight, 
tired ... came to clinic...got tested”. Frank went to a traditional healer when 
he first started to feel ill all the time. 
Kamy “ ...was getting sick all the time ... coughing, flu, feeling hot and sweating ... 













Table 4.4A:  Symptoms  and opportunistic infections experienced by the participants 
                 Participant No. 1 to 13 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
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4.5  Treatment Factors 
These include the complexity of the regimen, duration of treatment, immediacy of beneficial 
effects, adverse side effects and the availability of medical care providers to deal with 
problems related to treatment (WHO, 2003).  
 
The results tabulated in Table 4.5A indicate the wide range of side effects experienced by the  
participants.  The researcher is of the opinion that a checklist approach to listing side effects 
may have yielded more responses to the side effects experienced.  However responses elicited 
through an interview may indicate more realistically the felt experiences of taking the 
medication. All participants experienced side effects to some extent when treatment was 
initiated.  The responses to the side effects were varied; from experiencing very little side 
effects for a few days or a week to really struggling with adverse side effects for a few weeks 
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or even months. Three participants experienced very little side effects;  the side effects were 
hardly of any concern to them.  One participant suffered from the side effects of all her 
prescribed medication which included ART, TB medication and medication for opportunistic 
infections (bactrim and fluconazole).  After nine months, upon completion of her TB 
medication, taking medication become much easier as her pill burden reduced considerably.  
After some time on ART she was very concerned about lipodystrophy and so d4T was 
changed to AZT which she is more comfortable with.  Two participants described really bad 
side effects initially that lasted for about a month after which taking medication was like 
“eating sweets every day”. The other seven experienced side effects to some extent, which 
may be described as moderate and very manageable. Most importantly, all the participants 
expressed that the side effects became tolerable as they persevered with their treatment 
regimens. No life threatening side effects were experienced by any participant upon initiation 
of therapy.  One participant experienced lactic acidosis as a consequence of being on 
treatment for a few years; emphasizing the importance of careful and regular monitoring 
when taking ART.     
 
All the participants experienced side effects, but their reaction to the side effects and how 
they experienced the side effects varied quite considerably. This demonstrates that people 
react very differently to similarly prescribed medication, indicating the importance of 
individual monitoring and information and education for persons on treatment.  Moosa 
(2007) asserts that it is vital to educate persons on ART about potential adverse medication 
side effects and to ensure that they know what to do or who to contact if they experience such 
events.   
 
Table 4.5B gives an indication of the spread of regimen factors that were of concern to the 
participants. Most of the participants found the regimens relatively easy to take with only one 
participant complaining about the pill burden, two having swallowing difficulties and two 
sharing that initially they found taking ART difficult. ART involves three or more tablets and 
if medication for opportunistic infections are indicated as well then the increased pill burden 
and increased side effect profile is a concern, once again emphasizing the importance of 
initiating treatment before the person becomes susceptible to opportunistic infections. 
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One participant shared that she refused treatment initially because she was in denial about 
being infected with HIV.  She was counselled into taking ART because she became 
extremely ill.  ART was for this participant life-saving medication considering her CD4 count 
of 17cells/mm³ (dangerously low) and the two opportunistic infections she acquired 
(cryptococcal meningitis and TB).  
 
Most of the participants (9 out of 13) were really ill or symptomatic, and presented with 
opportunistic infections when they first started ART.  Despite the difficulties they may have 
experienced because of adverse side effects and pill burden, all the participants appear to be 
adhering optimally to their prescribed treatment. 
 
Below are participant quotes and responses to illustrate the range of side effects and regimen 




Mel “I can’t say it’s awful ...Side effects irritating at times, lactate problem and 
severe lipodystopy, insomnia (with stocrin), cramps and nausea (comes and 
goes ... doesn’t go away after two weeks) ... didn’t stop me from taking 
medicine but could affect them taking ARVs.   
Sharon “They are quite big ... and have to take all your tablets ... got stuck and I 
could feel it in my throat ... coughing and trying to swallow .... felt like 
bringing up ... didn’t feel like eating ... Thank goodness those nightmare 
tablets have stopped (on newer treatment regimen ... less tablets and easier to 
take”(difficulty swallowing). “Soon there will be only one, take at eight in the 
morning and eight at night”. 
Joyce Joyce shared that taking ARVs is no problem at all.  She shared that before 
she started treatment she had headaches and a rash but once she started 
treatment everything went away (immediacy of beneficial effects).  She also 
said that all side effects were explained to her during the counselling 
(information sessions). 
Futhi Futhi experienced very little adverse side effects. Futhi stated that people often 
go for treatment when it is too late. 
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Trace Trace shared that she initially refused treatment and then became very ill. 
Only then did she take treatment and she is pleased to say that her recovery 
can only be described as remarkable (immediacy of beneficial effects).  
Lipodystrophy is not a problem for her, but Trace does believe that this side 
effect can contribute to non-adherence (adverse side effects of ARVs). 
Wini Wini explained that she is suffering with pins and needles that does not seem 
go away.  She does however assert that this is not a problem as she is 
convinced that the discomfort will subside once her pregnancy is over 
(medication side effect). Wini expressed that she doesn’t forget anymore as 
something in her head reminds her at 9 o’clock and her son knows that 
9o’clock is medicine time (treatment routine).  Wini then went on to explain 
that taking the medication is not that difficult (complexity of treatment 
regimen). 
Thoks Thoks shared that she suffered for nine months with nausea, vomiting and 
stocrin made her go crazy and she had funny dreams (adverse side effects).  
She found it very hard to swallow the tablets as she was prescribed TB 
medication, ARVs bactrim and flucondazole (difficulty swallowing; pill 
burden).  She also shared that she had to switch drugs because d4T gave her 
lipodystropy (adverse side effect).  The TB medication made her skin go black 
(adverse side effect).  She was full of praise about the support she received 
from the doctor and the HIV counsellor at her workplace (availability of 
medical support for problems associated with treatment). Thoks shared that it 
was difficult in the beginning to take her medication as prescribed. She 
doesn’t have a problem now and takes her medication as prescribed. She uses 
a cell-phone reminder and is adamant that she does not forget to take her 
medication.  She takes her medication at six in the morning and at night 
(treatment routine). She is on lifelong treatment for opportunistic infections. 
Thoks also suffered the consequences of accessing treatment late as she 
succumbed to cryptococcal meningitis and TB (opportunistic infections). 
Thoks shared that she has personally experienced people she knows accessing 
treatment much too late (accessing treatment late). They are very weak when 
they eventually decide to take ARVs and just cannot tolerate the medication, 
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so they die. 
Nosi  Nosi found the side effects to be tolerable although stocrin kept her awake at 
night and she felt nauseous and couldn’t eat when she first started treatment 
(adverse side effects). Nosi shared that she takes her tablets religiously at 7:30 
every morning and every night but she did confess that taking tablets can be 
hard at times especially if your are at a bus stop or in a taxi (treatment 
routine). 
Kay Kay decided to seek treatment only when he started feeling sick often 
(accessing treatment late). Kay was badly affected by the side effects of his 
medication especially the stocrin. He felt like vomiting, lost his appetite, felt 
stressed as he had nightmares and often felt like he was seeing things (adverse 
side effects).  All of this went on for about a month. Kay also felt very hot and 
had to shower to feel better. Kay explained that after a few weeks the side 
effects settled and now taking medication is like eating sweets every day.  If 
he has to go out at night he takes his medication with him and he keeps 
medication at work as well because he is a shift worker (treatment routine, 
organised) 
Bob In the beginning Bob found taking medication confusing.  Bob would forget to 
take his medication initially when he started treatment and now uses a cell 
phone to remind him to take his medication.  He felt giddy when he initially 
started taking ART and explained that the giddiness lasted for about a week 
and then settled. He is however convinced that the medication caused him to 
have body shape changes (lipodystrophy) and insisted that his doctor change 
his medication to the next line treatment option.  Bob’s doctor explained that 
he would have liked Bob to remain on the first line for as long as possible 
because that is a patient’s best chance of effective treatment.  Regimen 2 has a 
much larger side effect profile and is more difficult to take and also treatment 
options after Regimen 2 are not readily available as yet.  
Andy Andy was diagnosed with HIV when he became very ill with shingles 
(opportunistic infection) and was advised to take ART almost immediately.  
He experienced very little side effects with his ART.  He felt much better 




Frank Frank first thought that the medication won’t help.  He first went to the 
traditional healer and only when that did not work did he go to his workplace 
clinic.  In the beginning it was difficult for Frank to take his pills as he was 
drinking alcohol as well... “everything comes out” but things got better after a 
while. His doctor explained about drinking and taking medication.  He also 
uses a cell phone reminder to take his pills on time. He has a routine; taking 
tablets at 6am and 7 pm and he has his wife and older children who also 
remind him. Frank’s wife gets her medication from Greytown because Frank’s 
sister is nurse at the hospital in Greytown even though the family live in 
Tongaat.  Frank explained that his wife goes to Greytown because no one 
knows her there so she feels safe to access her ART there ... “can see that 
people sitting in that queue are waiting for ART” ... that is what happens in 
public clinics and hospitals and if she goes to the clinic in Tongaat everyone  
will know her HIV status”.  
Kamy Kamy experienced about three weeks of bad side effects.   He experienced bad 
dreams and his body started shaking.  His doctor had to change his tablets and 
since the change he is feeling much better.  He said that after about three 
weeks “things came right”. He has established a routine for taking his tablets; 
just after his morning shower and at night after supper.  He also uses the news 
on TV as a reminder to take his medication. He keeps extra pills in a bag just 
in case he forgets and is at work. He is clear that it is important to follow the 
procedure “if you want to make your life better, follow the procedure” (he 
means take the tablets as you are suppose to take them). He also is clear that 
you must be organised. He says there is nothing difficult about taking his 









Table 4.5A:  ART Side Effects 
ART factors 1 2 3 4 5 6 7 8 9 10 11 12 13 
nausea x x   x  x x      
vomiting  x     x  x   x  
cramps x             
headache   x           
rash   x           
skin black       x       
body shaking             x 
loss of  appetite  x      x x     
pins and needles      x        
lactate problem x             
lipodystrophy  x    x*  x   x    
fever         x     
giddy/dizzy          x    
insomnia x       x      
Going crazy 
/seeing things 
      x  x     
nightmares       x  x    x 
very little s/e  x  x       x   
s/e tolerable x x x x x x x x x x x x x 
 s/e bad 
(initially) 
      x  x    x 
x  =  indicates side effect experienced by participant 










Table 4.5B:  Regimen factors 
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z  =  refused treatment initially 
y =  knows from own personal experience someone who accessed treatment too late 
x  =  participant experienced this 
 
ART are responsible for a broad range of side effects or toxicities ranging from low-grade 
intolerances that may be self-limiting to life threatening events. It is essential for ART 
adherence, and for the person on treatments safety, that health care providers and person’s on 
treatment are informed and educated about the potential toxicities that may be associated with 
ART so that the appropriate measures are taken to alleviate or eliminate the potential harmful 
effects of treatment  (WHO HIV/AIDS Programme, 2006).  ART related side effects may 
occur early (within the first few weeks or months of therapy) and late (after six or more 
months of therapy) and these adverse events may range from mild and tolerable to severe and 
life-threatening (WHO HIV/AIDS Programme, 2006).  Adverse ART related side effects are 
common and may result in discontinuation of treatment or erratic adherence. Mild to 
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moderate side effects are managed symptomatically and serious side effects may necessitate 
discontinuing the causative agent (Moosa, 2007).  It must be emphasised that the benefits of 
ART far outweigh the risks; ART is well tolerated by the vast majority of persons in need of 
this life-saving treatment, and most side effects are manageable (Moosa, 2007).   
 
All the participants in this study experienced side effects to some greater or lesser degree as 
well as regimen factors that made taking medication difficult. However all appear to be 
adhering optimally which means that all the participants are able to tolerate ART as life 
saving medication, a finding supported and  explained by Moosa (2007). 
 
4.6  Personal Factors that may Influence Adherence 
A wide range of personal factors emerged from the responses. Below are the participant 
responses.  The responses were then sub-categorised according to themes for analysis and 
presented. 
Participant Responses 
Mel “I think that intrinsically I know I have to be on this medication to get by day 
to day...” “I know I have to take this to be alive”.  “I believe that ARVs are 
lifesaving medicine ...   I believe your mind is stronger than that ...” (attitude 
and belief)...“HIV to me is like a walk in the park when I compare it to 
cancer”. “Have to worry about stigma when you have to fetch from the clinic 
in your community because the clinic sister knows my neighbour and this one 
and that one”.”HIV is the loneliest disease in the world. You see at 
Christmas how they hug and kiss you ... since I am HIV+ it is hard for them 
to hug and kiss me.” “Can’t get a work visa” (stigma and discrimination) 
Mel is completely open about her status but regrets going public about her 
status (disclosure).   “Most motivational speakers do not tell you the truth 
about being positive ... I will tell you ...I fall apart sometimes when I feel the 
hurt ... you smile ... but when you sleep in your bed alone at night there is no 
way that you are not feeling the pain of what people say in front and behind 
your back”. “You are treated like a dirty leper when you are HIV positive 
and to really get back your self esteem and self confidence is very difficult ... 
so often people become quiet and withdrawn or very angry and 
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venomous”(stigma and discrimination).  “Make sure myths about HIV are 
dismissed before the process starts ...lots of myths about libido ... many 
things ... white person’s means of controlling you ... mustn’t let that white 
doctor see you, it is like a conspiracy theory because it can’t be because of 
the sex” (denial of behaviour as a cause of HIV, myths, culture and lay 
beliefs about illness and treatment).  “Secrecy thing ... hide and have to take 
later then you forget”. (secrecy and non-disclosure).  “Also trust issues, who 
started making this medication and selling it ... the white people”.  “Some 
‘black’ people prefer traditional medication and even if some died of HIV 
they will say no, it is muti” (attitude and belief; knowledge and 
understanding; culture and traditional medicine) 
Sharon “lots of people are not telling about their status, it’s secretive, you just have  
to eat properly and take your medication and that’s it ... you will live, I don’t 
look at myself as being sick ... I just have something that I have to fight , “ 
living for my daughter”.  (secrecy and normalisation) “Some people find it 
difficult because they can’t drink and smoke”. (forgetting to take 
medication).“Discovery sends me updated stuff to educate me ... they show 
you pictures of what will happen if you don’t take your medication ...look like 
a scarecrow”. “If people don’t know your status and they compliment you ... 
this boosts you up, it makes you feel good, I won’t stop taking my medication, 
I have too much to live for”. 
Joyce Joyce is keen to keep her status private and to disclose only to a select few 
people.  She has disclosed to her employers, a friend and her husband and 
daughter.  She will not tell her in-laws as she says that they talk badly about 
HIV and ARVs (judicious disclosure). Joyce is determined to stay on her 
treatment because she has young children including a baby who is only two 
years old, “want to live for my family, for my children” (parenthood and 
responsibility).  Joyce shared that she is healthy now and she is determined to 
stay healthy.   She went on to explain that once on ARVs there are lots of 
rules but the rules make you take your medication. She was scared of all the 
rules but she realised that she needs the rules in order to take the medication 
properly, “if it’s hard then I will destroy my life. In my mind I have to take 
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...” (self-efficacy). Joyce shared that she knows of lots of people who are 
scared to let their employers know as they fear they will be fired (secrecy, 
fear of disclosure, hiding to take medication may negatively affect 
adherence) 
Futhi Futhi believes that alcohol and drug use may cause some people on ARVs to 
forget to take their medication (forgetting). She has witnessed this first hand 
with the father of her child. He is educated, a teacher but he drinks and 
forgets to take his medication and is often sick. Futhi also shared that to her 
knowledge some people still don’t believe that ARVs work and they prefer to 
take traditional medicine. She uses a cell phone reminder but says that taking 
the medication is a habit and she just can’t forget (treatment routine). Futhi 
emphasised that her son is her motivating factor as she must live for him to 
look after him and she wants to see her grandchildren (motivating factors, 
parenthood and responsibility).When questioned about stigma, Futhi shared 
that stigma attached to being HIV positive is not as bad as before as she has 
disclosed to close friends and family and they didn’t “isolate” her (stigma). 
Futhi explained that HIV is just like TB, or sugar diabetes (normalisation). 
Trace Trace felt strongly that her faith in God helped her cope with her illness; she 
is sure that God spoke to her (spirituality and religion).Trace believes in 
ARVs (attitude and beliefs about treatment), and she concurred that stigma is 
not so bad now (stigma). 
Wini Wini described having HIV as just like a normal sickness like heart disease 
or sugar diabetes (normalisation).  Wini explained that she used to forget but 
her husband would remind her to take her medication (forgetting).  This lady 
explained that drinking, smoking and a hectic lifestyle will not help 
adherence to medication.  She felt strongly that plain irresponsibility was also 
a reason for non-adherence (responsibility). 
Thoks Thoks believes strongly that faith and God helped her to cope with HIV 
infection. She prays for God’s help with the medication (spirituality, religion, 
self efficacy).  Thoks shared that she wants to live for her children; she needs 
to be there for them and her children are her motivation (parenthood and 
responsibility, motivation). Thoks went on to emphasise that being HIV 
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positive is really not the end of the world. She stated that it is important to be 
strong and to have faith in the ARVs (attitude and belief).  She also stressed 
that education about HIV infection is very important (knowledge and 
understanding). Thoks believes strongly that denial about HIV infection will 
prevent people from accessing treatment for HIV infection (denial; disbelief 
in diagnosis).  Thoks is aware that traditional medicine is the preferred 
medication for some people in need of ARVs or people mix their ARVs with 
traditional medication (culture and traditional medicine).   
Nosi Nosi is completely open about her HIV status; she told everyone at work 
because rather than have them talk behind her back.  She wanted her HIV 
status to be out in the open (disclosure).  Nosi revealed that when she found 
out her HIV status she went to her pastor and they fasted and prayed and this 
gave her the strength to deal with being HIV positive (religion and 
spirituality).  Nosi also explained that she was terrified about how she was 
going to take medication for the rest of her life but the fear of dying; just the 
thought of dying was enough to make her take her medication (fear of dying).  
Nosi went onto share that it is “your attitude” that gives you strength to deal 
with HIV and she learnt that ARVs will keep her alive and well (attitude and 
belief).  Nosi said that some people take their medication when they are ill 
and then stop when they feel better.  Nosi explained about how she developed 
TB while on ARVs.  She felt that a lot of stress in her life and not being able 
to eat made her susceptible to TB even though she was taking her ARVs. 
Nosi felt strongly that denial  was big in her community; people just deny 
that they may have HIV (denial). Nosi also felt that pressure from friends 
who live like there is no tomorrow may negatively impact on adherence 
behaviour (peer pressure).  Nosi also felt that education is important and she 
accesses lots of information from her doctor so that she gains knowledge 
about HIV infection (knowledge and understanding).  
Kay Kay was initially shocked to learn that he was HIV positive.  Kay has 
accepted his status and views his medical condition as a normal part of his 
life that he has to deal with.  He believes he must be positive and that he 
mustn’t be scared and that he must face this disease.  He stated that one must 
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be aware of one’s status, take medication and live a healthy lifestyle; Kay 
exercises (plays golf), and he does not smoke or drink (attitude, belief and 
healthy lifestyle).  Kay firmly believes that education and sport are important 
for living healthily with HIV. Kay has also realised the importance of 
accessing treatment early, not waiting to get sick and stated that if people 
come early for treatment they will be helping themselves. Kay does not 
believe in traditional medicine and only seeks medical advice from his 
doctor.  He is religious and his father is a pastor. He believes that prayer does 
help one to cope with living with HIV. Kay has only disclosed to his wife and 
will not let his parents know of his status.  He believes that one has to be 
careful about who one discloses to as he often hears people say “not nice 
things” about those who are HIV positive.  
Andy Andy stated that his doctor explained three very important things to him – no 
drinking, sex with condom and taking medication on time.  Andy believes in 
healthy living and having a good night’s sleep. He tries to get eight hours of 
sleep each night; he eats healthily and exercises (his work is physical and he 
does lots of walking and housework).  He believes that if he does what he is 
expected to do then he will live long.  He stated “you have to be organised 
...sleeping times can change ...then have to change my meds times ... just 
have to remember”.  He sets his alarm (cell phone alarm) as a reminder to 
take medication.  Andy stated that some people feel that it is better not to 
know your status than to know your status (fear of stigma and 
discrimination). 
Bob Bob has confidence in ART. He also stated that he has self-belief and went 
on to state “I believe that I will live to 100 years if I take my medication on 
time, eat healthy and condomise”.  He went on to state that he believes in the 
health care he receives and he is responsible for his own life. He is the boss 
of his life.  Bob clearly believes that ART decreases his viral load and will 
“extend his time of living”.  He is stated that “if I‘m living the virus is living 
and if I am dead the virus is dead, I am the boss, Take medication and kill the 
virus”.  Bob also believes that he must read and gain more knowledge and 
understanding, “must know the rules and follow the rules to kill the virus”. 
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He believes in traditional medication, but not for HIV/AIDS. Bob shared that 
ART has helped him regain his health and strength.  He believes that if he 
takes his medication he will “come right”.  He believes that he must listen to 
his doctor, take his medication and live healthy as he needs to live for his 
girls and his wife. Bob and his wife believe that their HIV status is a private 
matter.  He stated that even the church did not talk much about HIV except to 
tell young people to be careful about getting infected. Bob shared that some 
people did not believe that ART works.  These people believe that traditional 
medication can cure HIV.  Bob felt strongly that the government must stop 
these rumours.  
Frank Frank first went to a traditional healer with his symptoms and only accessed 
ART when traditional medicine did not help him (culture and traditional 
medicine). Frank knows from his own experience that taking alcohol with his 
ART is not the correct thing to do.  Frank says that he must be healthy and 
strong for his job. His job is very physical so he is exercising while working.  
He gave up drinking and smoking to be healthy. He believes that sometimes 
people don’t understand about the pills that is why they don’t take them. 
“must teach them to take their pills” ... “just take pills and you will get 
better” (demonstrates his belief in his medication and importance of 
knowledge and understanding). 
Kamy Kamy was shocked to hear of his HIV status ... as he thought his life was 
finished because he had HIV. Kamy runs, exercises and eats healthy ...no 
smoking or drinking ... “My life is my life ...and I must listen to my doctor ... 
doctor says it’s up to you to take the treatment right, I do what the doctor 
tells me ....even now (meaning after being on ART for so long) No problem”, 
(no problem taking medication).  Kamy is even interested in additional 
supplements that can make him healthier, and he is willing to buy these 
supplements himself.  He shared that alcohol and smoking will make you 
forget to take your medication and said “tobacco is not good on the blood”.  
Kamy stated that being HIV positive and taking medication should be treated 
just like other any other chronic condition for example diabetes, “forget you 
are HIV  ...think positive ...just like any other sickness ....like sugar diabetes” 
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(wants HIV to be treated just like any other chronic disease, normalisation of 
HIV/AIDS).  Kamy stated that “I know I have to take my medication ... 
nothing can stop me ...treatment make my life perform ... I work better”.  He 
is interested in a support group because he feels that sharing his story may 
help others. Kamy does not believe in traditional medication.  He believes in 
ART. Kamy is willing to share his knowledge and experience of taking ART 
with other HIV positive people.  He knows that the treatment works and he 
can explain this to others.  Kamy explained what happens if one forgets to 
take ARVs and he understands how important taking his medication as 
prescribed is (attitude, belief, knowledge and understanding).  
 
Result Analysis   
Below is the discussion relating to the themes extracted from the data. 
 
4.6.1  Positive Attitude and Strong Beliefs about the value of ART 
All participants in this study believed in the value of ART as life-saving medication.  All the 
participants in this study were determined to adhere optimally because they believed in their 
treatment and because they wanted to stay strong, healthy and alive. These findings were 
supported in the literature as adherence is likely to be enhanced in people who strongly 
believe in the efficacy of HAART (WHO, 2003).   Key facilitators in the Dahab et al. (2008) 
study include amongst others a strong belief in the value of treatment which is in accordance 
with the findings of this study.  
 
Below are a few quotes and responses that were selected to give an idea of the participant’s 
attitudes and beliefs to ART.  
Mel “I think that intrinsically I know I have to be on this medication to get by day to 
day, I believe that ARVs are lifesaving”. 
Sharon “ I won’t stop taking my medication; I have too much to live for”. 
Bob “I am the boss; take the medication to kill the virus”. 
Kamy  
 
“I know I have to take my medication ... nothing can stop me, my treatment 
make my life perform, I work better”. 




Nosi She shared that it is your attitude to HIV/AIDS that gives you strength and it is 
your belief in ART that makes you keep taking your medication. 
Kay He believes he has a positive attitude that allows him to face this disease and 
he is not afraid of fighting this disease. 
 
4.6.2  Stigma, Secrecy, Discrimination, Disclosure and Denial 
Only one participant, Mel was completely open about her status. The other participants 
except for Sharon, disclosed their status albeit discretely, only to close family, or to close 
family and friends.  Sharon was adamant that her close family not know her status.  She 
disclosed to a work colleague and a close friend she could trust.  Mills, Nachega, Buchan et 
al. (2006) and Naidoo (2009) found that individuals who disclosed their HIV status to close 
family or friends are more likely to be adherent than those who had not disclosed.  Gilbert 
and Walker (2009) found that disclosure was the biggest challenge in getting persons to 
adhere to their prescribed treatment.  All the participants disclosed to at least one or more 
persons, therefore disclosure is likely to influence adherence behaviour positively.   Most of 
the participants felt that when people have to hide and take their medication then they may 
not always be in a position to take their medication as prescribed.  This finding was supported 
by the Dahab et al.’s (2008) study which found that both health care providers and persons on 
treatment reported that fear of stigmatisation caused persons who had not disclosed their HIV 
status to hide their HAART or skip doses when in the presence of others.  Inungu and Karl 
(2006) assert that stigma is of utmost concern because it is both the cause and effect of 
secrecy and denial.  Secrecy and denial cause people with symptoms of HIV infection to 
claim that they suffer from less stigmatised diseases such as cancer, thus preventing them 
from accessing life saving ART (Inungu & Karl, 2006). Two participants felt that the stigma 
associated with HIV was not as bad as before.   
 
Participant responses and quotes about their experiences with regard to stigma, secrecy, 
discrimination, disclosure and denial. 
Mel She is open about her status but shared that if you “hide and have to take 
medicine later, then you forget”.  She also shared that some people are in 
“denial of behaviour that can cause HIV”.  
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Joyce She explained that some people feared being fired if they disclose their status to 
their employers and hiding and secrecy can lead to problems with taking 
medication.  
Sharon She said, “lots of people are not telling about their status ... it’s secretive”. 






These participants disclosed to a few select people; their immediate family, 
employers and a friend. Futhi stated that she was not “isolated” when she 
disclosed her status and she stated that “stigma about HIV is not that bad 
anymore; not like before”. Thoks and Nosi stated that they were aware that 
denial about HIV infection will prevent people from accessing ART and Nosi 
added that denial is big in her community. 
Trace She stated that when she disclosed her status she realised that the stigma around 
HIV is not so bad now. 
Frank He is aware that “some people just don’t believe they have HIV ...give them 
pills and they don’t take it”(denial). 
Kay and 
Bob 
They shared that you must be careful who you disclose to and they only 
disclosed to their wives. 
Andy He shared that some people felt that they would rather not  know their status  
because if you know then you have to deal with it (denial). 
 
4.6.3  Education and Knowledge about HIV/AIDS 
Five of the participants stressed that knowledge and understanding was important for 
medication adherence.  One participant shared from his own experience that some people 
may be non- adherent because they do not understand the importance of taking ART as 
prescribed.  This finding was supported by Vervoort et al. (2008).  According to Vervoort et 
al. (2008)  people on treatment should receive information about their medication that is 
appropriate to their level of understanding because, in this way, individuals receive 
information that will guide them toward behaviours that will enhance adherence. 
 
Participant quotes and responses with regard to knowledge and education about HIV/AIDS 
are tabled below. 
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Thoks, Nosi, Kay, Bob, 
Frank and Kamy 
 These participants stated that knowledge and understanding is 
important for taking medication properly. 
Frank He shared that “sometimes people don’t understand about the 
pills, that is why they don’t take them ...must teach them to take 
their pills”, emphasising the importance of knowledge and 
understanding of prescribed ART for adherence. 
 
4.6.4  Traditional Medicine 
Three participants stated that they were aware of people in need of ART who may not access 
ART but opt for traditional medicine only.  One participant was aware of people mixing 
traditional medicine and ART.  One participant made it clear that he believed in traditional 
medicine but not for HIV/AIDS, and one participant accessed ART as a last option after 
realising that traditional medicine did not help his HIV infection.  All participants in this 
study were careful about not using traditional medicine with ART because of the information, 
knowledge and counselling they received about taking ART. 
 
The fact that participants reported knowing that some people still prefer traditional medicine  
for treating HIV infection was disconcerting because people with those beliefs are being 
denied life-saving medication. As reported, people who mix traditional medicine with ART, 
and people who stop ART while they are taking traditional medicine risk suboptimal levels of 
ART which has serious implications ( Aspeling and van Wyk,  2008; Dahab et al., 2008). 
 




These participants stated that “some people prefer traditional medicine to 
western medicine” and Thoks added that some people “mix traditional 
medicine with ART”. 
Bob Bob believes in traditional medicine but not for HIV/AIDS.  He shared that 
some people did not believe that ARVs work and he felt strongly that the 
government must stop such rumours. 





4.6.5  Normalisation of HIV/AIDS 
Most of the participants shared that they have accepted HIV/AIDS just like any other illness 
or disease that is affecting people in the world today.  Most of the participants expressed that 
they do not see themselves as different; they have an illness, just like any other chronic 
illness and they can live a normal life if they take their medication as prescribed.  This 
finding was supported by Gilbert and Walker (2009) who found that a process of 
normalisation was taking place regarding HIV/AIDS being viewed as a chronic condition 
such as diabetes or hypertension. Even though most of the participants expressed that they 
accepted HIV disease, just like any other chronic condition they were not open about being 
HIV positive, only disclosing their status to  close family or friends whom they could trust.  
 
Cameron (2005) asserts that talking about HIV/AIDS and accepting HIV as just a virus; just a 
disease may help with the realisation that there is nothing shameful about having HIV or 
AIDS.  If people can talk about it, then they can normalise it and the sooner HIV is seen as a 
normal disease, the sooner people will be able to deal with it unemotionally, effectively and 
efficaciously (Cameron, 2005). According to Gilbert and Walker (2009) if the process of 
normalisation continues and gathers momentum it has the potential to reduce the stigma 
associated with HIV/AIDS and its negative effects.  Castro and Farmer, (in Gilbert and 
Walker, 2009) state that access to ART triggers a ‘virtuous social cycle’ by alleviating the 
visible signs of HIV disease, facilitating a return to a normal productive social life (Mahajan 
et al., in Gilbert and Walker, 2009), thus further normalising the experience of living with 
HIV/AIDS. 
 
Below are some participant responses that shed light on normalisation of HIV/AIDS. 




They explained that HIV is just like TB or sugar diabetes, “forget you are HIV 
positive ...you are sick just like other sicknesses, like sugar diabetes ....no one 
can see that you are HIV positive ... just keep healthy”. 
Thoks She said “HIV is not the end of the world”.   
Kay He accepts HIV as a normal part of his life.   
Sharon Sharon shared “you have it, admit you have it ...eat healthy, take meds and 
live a normal life ... I don’t look at myself as being sick, I just have something 
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that I have to fight”. 
 
4.6.6  Motivating Factors – Parenthood and Responsibility 
Most of the participants with young children and families shared that their motivation for 
adhering and staying healthy was because of their responsibility as a parent, a provider and a 
spouse. These participants spoke passionately about their responsibilities and they were 
determined to stay healthy.  This finding was supported by Aspeling and van Wyk (2008) 
who found that the responsibility of parenthood and the desire to raise one’s own children 
were huge motivating factors for optimal adherence to ART.  Gilbert and Walker (2009) 
found that children were a strong motivating factor for adherence and  Kajee (2008) stated 
that for many persons, concern for the well-being of their children brought into focus the 
need for good adherence in order to remain healthy and thus continue caring for their 
families, which is in accordance with the findings of this study. 
 
Participant  responses about parenthood and the responsibility that goes with this role. 
Sharon Her main concern and reason for living is her child, “living for my young 
daughter, my child”.   
Joyce She is determined to stay healthy because she has young children, including a 
baby. 
Futhi She shared that her son and living to see her grandchildren is what keeps her 




She lives for her children and her children are her motivation. Bob shared that his 
wife and children motivate him and he needs to live for them. 
 
4.6.7  Lifestyle Factors 
Most of the participants were intent on a healthy lifestyle because they felt that eating 
healthily, exercising and making choices to be organised and responsible helped with 
adherence. Most of the participants lived a quiet life with their families and one participant 
mentioned that staying in one place makes it much easier to take ones medication as 




Three participants stated that alcohol and drugs may lead to forgetting to take medication.  
This finding was supported in the literature by Frank and Duncan (2009) who reported that 
alcohol and drug abuse may affect a person’s ability to remember to take their medication. 
Pratt (2003) stated that difficulties with adherence may be associated with the chaotic 
lifestyle of people who abuse alcohol or drugs. Wini’s statement about a hectic lifestyle 
alludes to this. 
 
One participant reported that stress made her vulnerable to opportunistic infections and she 
was adamant that she was not non-adherent. This finding was not in accordance with the 
literature which states that untreated stress and depression are strong predictors of non-
adherence, which may then render a person susceptible to opportunistic infections. 
 




Kay, Andy, Frank and Kamy shared that they try to live a healthy 
lifestyle; they exercise, eat healthily and they do not indulge in alcohol 
or smoking.  Frank gave up alcohol and smoking to be healthy. This 
helps them to adhere to their medication. Kay, Andy and Kamy shared 
that it is important to be organised when you have to take ART, “you 
have to be organised...sleeping times can change... then you have to 
change medication times ...you just have to remember”. Mel and Bob 
felt that people who struggle with routine may not be adherent.  Mel, 





Wini felt that plain irresponsible behaviour and living a hectic lifestyle 
will cause problems with adherence, and people on ART must be 
responsible. Nosi shared that living like there is no tomorrow will 
impact negatively on adherence. Frank and his family live a quiet life.  
After work Frank goes home to his family. Frank occasionally takes his 
family to their farm on weekends, “no partying ... only work and family 
and church”. Kamy shared that it is better to stay in one place as it 
makes it easier to take tablets. 






people to forget to take their ARVs.  Futhi, Wini and Kay shared that 
taking alcohol may cause adherence problems because you then forget to 
take your medication. 
Stress: Nosi felt that stress in her life made her susceptible to TB while she was 
on ART. 
 
4.6.8  Religion and Spirituality 
For three of the participants God was a very important part of coping with HIV/AIDS and 
adherence.  Their religious beliefs were strong and they were very expressive about how God 
helped them to cope with living with HIV infection. This finding was supported by  Konkle-
Parker et al. (2008) and Sanjobo et al. (2008) as these studies found that prayer and 
spirituality were important factors that facilitated adherence to ART.   
 
Participant responses about Religion and Spirituality 
Trace She felt strongly that God spoke to her when she was very ill and this helped 




They firmly believe that prayer and their faith in God helps them to cope 
with living with HIV/AIDS and to take their medication as prescribed. 
Nosi Nosi added that prayer and fasting gave her the strength to cope with 
HIV/AIDS. 
 
4.6.9  Forgetfulness 
All the participants shared that at some point in their lives they may have forgotten to take 
their medication.   This finding is supported in the literature and is the most commonly cited 
reason for non-adherence (Amberbir et al., 2008; Naidoo, 2009;  Tuldrà & Wu, 2002; WHO, 
2003).  Tuldrà and Wu (2002) state that persons on ART may really benefit from the use of 
adherence reminders.      
 
It must be stated that all the participants shared that they knew exactly what they must do if  
they forgot to take their ART because they understood the consequences of forgetting.  
Responses such as taking the medication as soon as they remembered, to the use of adherence 
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aids to minimise forgetting were mentioned. Table 4.6.9A below illustrates the findings of 
this study regarding adherence aids.  Most of the participants made use of adherence aids so 
that they would not forget thus enhancing their ability to adhere as prescribed. 
 
Below are participant responses and quotes about their experiences of Forgetfulness. 
Wini , Thoks, 
Andy, Frank  
and Kamy 
Wini and Thoks explained that initially they use to forget, but not anymore.   
Wini shared that something in her head reminds her at 9 o’clock and her 
husband and son know that 9 o’clock is medicine time (treatment routine). 
Andy, Frank and Kamy stated that they use to forget but not anymore as 
they are committed to taking ART and not forgetting.  Kamy also said “if I 
forget ...just take ...just open my bag and take my pills”. 
Mel and 
Bob  
Mel shared that from her experience, people who struggled with routine 
might forget to take their meds.  Bob struggled with routine initially and 
this made him forget to take his meds, but not anymore. 
Nosi ,Sharon 
and Mel 
Nosi and Mel said, “I just know I must take my ARVs ... if I forget ... then I 
take it as soon as I remember ....can’t skip medication”.   
Sharon shared that she used a pocket alarm clock and her mom and 
daughter would remind her about her medication when she came out of 
hospital (they did not know that she was on ARVs). 
Joyce Joyce said ... if you forget just take as soon as you remember and try to 
make sure you don’t forget again”. 
 
Table 4.6.9A:  Adherence Aids (Tools) used by participants 
 Numbers 1-13 represent the participants in this study 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
Cell phone 
reminder 
x      x   x  x  
Pocket alarm  x            
TV reminder             x 
Family 
reminders 
 x    x      x x 
Tx routine x x x x x x x x x x x x x 
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Table 4.6.9A displays the range of adherence tools used by participants to help them 
remember to take their medication as prescribed.  Amberbir et al. (2008) found that persons 
who claimed to use memory aids were three times more likely to be adherent than those who 
did not.   The Amberbir et al. (2008) study showed that adherence interventions should 
include memory aids and other reminders to help persons take their medication.  All the 
participants had a routine that positively influenced their ability to adhere.  Most of the 
participants used some strategy or aid to help them to remember to take their medication and 
this  is  likely to  maintain and enhance their positive adherence behaviour. 
 
4.6.10  Self-Efficacy 
Bob’s “ self-belief” and being in charge of his own life; Kamy’s statement about following 
the procedure to make life better; Mel’s intrinsic belief and Nosi’s strength all allude to the 
confidence most of the participants have regarding fighting this disease with all that is 
available to them.  This finding was in accordance with Heyer and Ogunbanjo’s (2006) 
explanation of self-efficacy as a person’s belief in his or her ability to take their medication as 
prescribed; an attitude positively associated with medication adherence. 
 
Below are the participant responses that allude to Self Efficacy. 
Bob Bob shared that he has “self-belief” that he will live to 100 because he takes his 
medication as is required. Bob also said, “ I am in charge of my life ...I am the boss 
of my own life”.  Kamy said, “...if you want to make your life better follow the 
procedure”. Nosi “I have accepted it, it’s part of my life now ... I take it as part of 
my life now ...I believe I am the strongest person”. 
Mel Mel shared “ I don’t have any factors that will prevent me from taking my 
medication”...” you have got to have that intrinsic thing ... I need to take this 
medication every day for the rest of my life because I want to live ... you have got to 
own your illness”.   
Joyce Joyce said ... “very easy ... I know it is my life ... if its hard then I will destroy my 






4.6.11  Health Improvement: Ambiguous 
One participant stated that some people on ART take their treatment only when they are very 
ill and then stop taking treatment when they feel well. This finding was supported by Kip, 
Ehlers and Van der Wal, (2009); Mills, Nachega, Bangsberg et al., (2006) and Sanjobo et al. 
(2008) who found that improved health could be a barrier as well as a facilitator to adherence.  
This study reported that some persons stopped taking their medication when they felt better 
while other persons were motivated to continue taking their medication when they 
experienced the benefits of treatment.  This finding indicates that the stage of treatment when 
persons start to feel better may be a critical turning point for interventions to maintain 
optimal adherence behaviour (Sanjobo et al., 2008). This reflects the need for ongoing 
counselling and education throughout the different periods to better understand the challenges 
of lifelong treatment so that the  necessary strategies may  be  introduced to  ensure  the  
maintenance  of optimal adherence behaviour.   
 
One participant shared that fear of dying was enough to make her take her medication 
because she wanted to live.  This finding is supported by the Gilbert and Walker (2009) study 
which showed that adherence to ARVs represent survival, health, and a future and non-
adherence meant death. 
 















Chapter 5:  Major Conclusions and Recommendations 
  
5.1  Major Conclusions 
“AIDS is above all a remediable adversity.  Our living and our life forces are stronger, our 
capacity for wholeness as humans is larger, than the individual effects on the virus.  Africa 
seeks healing.  That healing lies within the power of our own actions. In inviting us to deal 
with the losses it has already inflicted, and, more importantly, in enjoining us to avoid future 
losses that our own capacity to action make unnecessary, AIDS beckons us to the fullness and 
power of our own humanity.  It is not an invitation that we should avoid or refuse” (Cameron, 
2005 p215). 
 
This qualitative study was designed to explore the factors that influence adherence to 
HAART.  In-depth interviews conducted with thirteen participants as reflected in the analysis 
of data offered a rich description of the many factors that influence adherence. The results of 
this study supported prior research findings with regards to the factors that influence 
adherence.  The value of this study is that it may contribute to a deeper understanding of the 
complexities associated with lifelong adherence to HAART as well as inform strategies that 
may improve adherence behaviour.  The major conclusions based on the major findings are 
summarised in this chapter and appropriate recommendations are suggested.  
 
Social support emerged a great motivator of adherence behaviour amongst all the 
participants. All the participants emphasised the value of close family, friends, colleagues or 
just someone, as instrumental in enhancing their adherence behaviour. All the participants felt 
strongly about social support as a factor that positively contributes to adherence. 
 
Health care provider factors appear particularly significant because most of the participants 
shared their opinions about their interactions with their health care providers in great detail.  
All the workplace programme attendees were full of praise about the kind of care they 
received at their wellness clinic.  They felt privileged to be part of a programme where all 
people in need of healthcare attended the same facility.  No separate queue or clinic for 
persons in need of HIV antiretroviral therapy.  All employees in need of health services 
attended the same wellness clinic and saw the doctors or nurses regarding their health 
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concerns.  Issues concerning  confidentiality about their HIV status was not a concern.  The 
wellness programme  attendees were aware of the high standard of care that was made 
available to them by their employer.  They were full of praise for the caring and supportive 
health care providers they interacted with. This is an important finding that contrasts starkly 
with the South African public sector HIV programme where people have to attend the HIV 
clinic or stand in the HIV queue if in need of ART. Issues about confidentiality in the public 
sector were a real concern for some of the participants because this was the reason why their 
spouses travelled long distances to access ART.  Because of the stigma and discrimination 
still associated with HIV and having to deal with the additional stress of the HIV clinic may 
keep many HIV positive people from accessing treatment.   
 
Most of the participants accepted HIV disease as a chronic condition such as hypertension or 
diabetes. Most participants were not ready to be completely open about their HIV status and 
only disclosed a few trusted family and/or friends. They alluded to normalisation of HIV 
because this helped them to accept their status and to cope with HIV disease. 
 
Regarding confidentiality, the “Patient Rights Charter” documents the rights and 
responsibilities of health care users and health care providers. The charter states that all 
health care users have the right to be treated by a named health care worker; the right to 
confidentiality and privacy; the right to a second opinion and the right to refuse treatment.  
Lack of confidentiality emerged as a grave concern to participants and spouses who accessed 
ART in the public sector and none of the participants appeared to be aware of the fact that 
their health care rights were being violated. 
 
An interesting finding with regard to the employee wellness clinic was that even though this 
user friendly facility was in place with very understanding and supportive staff on hand to 
attend to the health needs of the employees, all the workplace attendees reported accessing 
treatment only when they experienced symptoms that were impacting on their daily 
functioning or when they presented with an opportunistic infection.   
 
With regard to socio-economic factors, although only a few participants reported their 
experiences of how they think poverty, transport, and child care costs may affect adherence 
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behaviour their input brings into awareness the daily challenges that South Africans endure 
and the effect these circumstances may have on adherence behaviour.  For optimal adherence 
to become achievable the underlying socio-economic factors that impact so heavily on the 
lives of the poor must be addressed.   
 
A wide range of side effects were reported by the participants but how the participants 
experienced side effects were varied and different. Some participants reported that side 
effects were hardly a concern, others experienced some side effects when they started 
treatment that were manageable while a small number experienced very bad side effects 
initially. However, the side effects were generally well tolerated by all the participants in this 
study and side effects did not appear to be high on the list of factors that negatively 
influenced adherence because in most cases the side effects were short lived and manageable, 
or the desire to live outweighed any negative influences. In other words the value placed on 
treatment far outweighed any discomfort they may have experienced and persons on 
treatment found ways to ensure optimal adherence. 
 
Personal factors were many and varied which once again emphasised the importance of the 
subjective influences of the individual in assessing how these factors may influence 
adherence. The responsibility that goes with being a parent, provider and spouse and caring 
for one’s family was a strong motivating factor for ART adherence. Lifestyle factors were 
also reported as very important facilitators of adherence and all the participants appeared to 
be particular about their lifestyle choices.  All lived relatively quiet lives; they ate healthily, 
exercised, were organised and responsible, and avoided alcohol.  All the participants in this 
study believed in the value of ART as life saving medication, therefore this factor also came 
out positively as a motivator for adherence behaviour. 
 
The personal experiences of how people cope or are affected by these factors differed 
considerably, even amongst a small sample of people. This highlights the importance of 
listening to the unique experiences of people and the value of working with small groups of 
people in order to find out about their experiences of the challenges they may encounter so 
that strategies can be tailored to meet their particular needs. The value of this study appears to 
be in the subjective experiences of the individual in a particular group of people and to 
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demonstrate the importance of the individual in a group when trying to understand the factors 
that influence adherence to ART and in tailoring interventions to support lifelong medication 
adherence. 
 
5.2  Recommendations 
The Health Minister, Dr Aaron Motsoaledi revealed in his May 2011 budget speech the four 
pandemics the country is burdened with. The HIV/AIDS and TB pandemic is by far the most 
severe, and costly, of the four. The other three are; unacceptable high maternal and child 
mortality (which is linked to HIV/AIDS), increasing incidence of non-communicable 
diseases and the pandemic of violence and injury. 
 
HIV/AIDS and TB is the greatest public health challenge facing SA. It is therefore important 
for South Africans to lend support to civil society organisations such as the Treatment Action 
Campaign (TAC), Section 27, Médìcins Sans Frontières / Doctors without borders (MSF) in 
their call for the South African government to commit to certain targets in the fight against 
HIV/AIDS and TB. The above mentioned groups have asked the South African government 
to commit to: 
• Place a minimum of 3 million people on ART by 2015; 
• Ensure that at least 80%  of public sector health facilities provide integrated 
HIV/AIDS  and TB services; 
•  Immediately and fully implement WHO treatment guidelines for ART initiation at 
CD4 count of 350; 
• Put in place a policy framework that will enable SA to increase access to affordable 
effective medicine; and 
• Actively support innovative financing mechanisms on both a national and 
international scale that provide robust funding for HIV/AIDS and other health 
programmes 
 
HIV/AIDS has been described as an absolute public health emergency which means decisive 
action should be prioritized in order to reverse the epidemic.  But HIV/AIDS is also not a 
disease that we are comfortable to talk about.  Judge Edwin Cameron speaks about the 
inexpressible relief he felt when he finally broke his silence on being HIV positive.  His act 
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of speaking out made him realise the simple truth, “There is nothing shameful about having 
HIV or AIDS. If we can talk about it, we normalise it. And the sooner we will be able to deal 
with it unemotionally and effectively. Normally” (Cameron, 2005:63).  Normalising 
HIV/AIDS as just a disease, like any other chronic disease may be the key to ending the 
stigma, denial and shame associated with HIV/AIDS. If people can talk freely about HIV 
disease then they may be encouraged and empowered to deal with the disease more 
proactively, efficaciously and effectively.  Further research with regard to normalisation of 
HIV/AIDS  is highly recommended as this may lead to a better understanding of how this 
factor influences adherence as well as other aspects of HIV/AIDS. 
 
Many HIV positive people are accessing ART both privately and in the public health sector. 
Health care providers and health care users must be educated about their rights and 
responsibilities as documented in the “Patient Rights Charter”. It is equally important that 
health care users know when their health care rights have been breached and about the action 
that should be taken if they find themselves in such a situation (TAC. Equal.  Issue 35, 
September 2010). 
 
Studies to explore the link between HIV medication non adherence and the social grant must 
be encouraged because the consequences of such behaviour has serious implications for the 
person on treatment as well as ART programmes. South Africa is one of the most unequal 
societies in the world and the impact of a person’s socioeconomic circumstances on their 
daily lives may influence their ability to adhere as prescribed. 
 
As persons live longer because of ART ongoing research will be necessary to explore the 
effects of treatment over time, the effects of treatment at different life stages, as well as the 
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New HIV Antiretroviral Treatment Guidelines released on the 1 April 2010  
Standardised National Eligibility Criteria for Starting ART Regimens for Adults and 
Adolescents in South Africa 
 
Eligibility Criteria 
Eligible to Start ART 
CD4 count <200cells/mm³ irrespective of clinical stage  
or  
CD4 count <350cells/mm³ 
In people with TB/HIV 
Pregnant women 
or 
WHO stage IV irrespective of CD4 count 
or 
MDR/XDR-TB irrespective of CD4 
Require Fast-Track* (i.e. ART initiation within 2 weeks of being eligible) 
Pregnant women eligible for lifelong ART 
or 
People with very low CD4 (<100 - 200cells/mm³) 
or 
Stage 4, CD4 count not yet available 
or 
MDR/XDR-TB 
Persons Not Yet Eligible for ART 
Persons are transferred to a wellness programme for regular follow up and repeat clinical 
assessment and CD4 testing 6-monthly. 
Persons receive advice on how to avoid HIV transmission to sexual partners and children 
INH prophylaxis is initiated if asymptomatic for TB. 
Persons receive contraceptive advice and for women a pap smear is recommended. 
*All other people should receive ART within 2 months of a clinical staging event or 
qualifying CD4 count 
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Standardised National ART Regimens for Adults and Adolescents in South Africa 
National ART Regimens  
1st Line:  All new persons needing treatment: 
TDF + 3TC/FTC + EFV/NVP  
For People with TB co-infection, EFV is preferred. For pregnant women or women of child 
bearing age, not on reliable contraception, NVP is preferred. 
Persons currently on d4T-based regimen with no side effects: 
d4T + 3TC + EFV/NVP  
Persons to remain on d4T if well tolerated. Early switch with any toxicity to d4T 
recommended. Substitute TDF if at high risk of toxicity (high BMI, older, female, TB 
treatment) 
Contraindication to TDF: renal disease 
AZT+ 3TC +EFV/NVP 
2nd Line:  Failing on a d4T or AZT-based 1st line regimen:  
TDF + 3TC/FTC + LPV/r  
Virological failure must be followed by intensive adherence management, as re-suppression 
is often possible. If repeat VL remains >1000 in 3 months despite adherence intervention, 
switch. 
Failing on a TDF-based1st line regimen: 
AZT + 3TC + LPV/r  
Virological failure must be followed by intensive adherence management, as re-suppression 
is often possible. If repeat VL remains >1000 in 3 months despite adherence intervention, 
switch. 
Salvage Therapy:  Failing any 2nd line regimen: 
Refer such persons to a specialist for assessment. Virological failure on protease inhibitors is 
almost always due to non-adherence. Therefore intensively exploring and addressing issues 
relating to causes of non-adherence will most often lead to re-suppression. If the VL remains 
high, refer where possible, but maintain on failing regimen. 
 






World Health Organisation Clinical Staging of HIV/AIDS for Adults and Adolescents 
with confirmed HIV infection 
 
The clinical staging and case definition of HIV for resource-constrained settings were developed by 
the WHO in 1990 and revised in 2007. Staging is based on clinical findings that guide the diagnosis, 
evaluation, and management of HIV/AIDS, and it does not require a CD4 cell count. This staging 
system is used in many countries to determine eligibility for antiretroviral therapy, particularly in 
settings in which CD4 testing is not available. Clinical stages are categorized as 1 through 4, 
progressing from primary HIV infection to advanced HIV/AIDS. These stages are defined by specific 
clinical conditions or symptoms. For the purpose of the WHO staging system, adolescents and adults 
are defined as individuals aged ≥15 years. 
Clinical Stage 1 Asymptomatic infection 
Seroconversion illness 
Persistent generalised lymphadnopathy 
Performance status 1 (fully active and asymptomatic) 
Clinical Stage 2 Mild symptoms 
Moderate unexplained weight loss (<10% of presumed or measured body 
weight) 




Recurrent oral ulceration 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections 
Minor mucocutaneous manifestations 
Performance status 2 (symptomatic but near fully active) 
Clinical Stage 3 Advanced symptoms 
Unexplained severe weight loss (>10% of presumed or measured body weight) 
Unexplained chronic diarrhoea for > 1 month 
Unexplained persistent fever (above 37.6°C  intermittent or constant > 1 month 
Persistent oral candida, chronic vaginal candidiasis 
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Oral hairy leukoplakia 
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or 
joint infection, meningitis or bacteraemia) 
Pulmonary tuberculosis (TB) (current 
Acute necrotising ulcerative stomatitis, gingivitis or periodontitis 
Unexplained anaemia (>8g/dl), neutropaemia (<0.5 x 10 power 9 per litre) or 
chronic thrombocytopaenia (<50 x 10 power 9 per litre)Performance status 3 (in 
bed <50% of past month) 







HIV wasting syndrome   
Extrapulmonary tuberculosis (TB) 
Pneumocystis carinii pneumonia (PCP) 
Recurrent severe bacterial pneumonia 
Chronic herpes simplex infection (orolabial, genital or anorectal of more than 
one month’s duration or visceral at any site) 
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
Extrapulmonary tuberculosis 
Kaposi’s sarcoma 
Central nervous system toxoplasmosis 
HIV encephalopathy 
Extrapulmonary cryptococcal (including meningitis) 
Disseminated non-tuberculous mycobacterial infection 
Cytomegalovirus (CMV) infection (retinitis or infection of other organs) 
Progressive multifocal leukoencephalopathy 
Chronic cryptosporidiosis (with diarrhoea) 
Chronic isosporiasis 
Herpes simplex virus ulcer > 1 month 
Oesophageal or  
Disseminated mycosis (coccidiomycosis or histoplasmosis) 
Atyptical mycobacteriosis 
Recurrent non-typhoid Salmonella bacteraemia 
Lymphoma (cerebral or B-cell non-Hodgekin) or other solid HIV- associated 
tumours 
Invasive cervical carcinoma 
Invasive cervical carcinoma leishmaniasis 
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symptomatic HIV- associated nephropathy or symptomatic HIV-associated 
cardiomyopathy 
Toxoplasmosis 
Performance status 4 (confined to bed > 50% of past month) 
Unexplained refers to where the condition is not explained by other causes 
 


























CDC Classification System for HIV Infection 
 
The CDC categorization of HIV/AIDS is based on the lowest documented CD4 cell count and on 
previously diagnosed HIV-related conditions (see below). For example, if a patient had a condition 
that once met the criteria for category B but now is asymptomatic, the patient would remain in 
category B. Additionally, categorization is based on specific conditions, as indicated below. Patients 
in categories A3, B3, and C1-C3 are considered to have AIDS. 
 CDC Classification System for HIV-Infected Adults and Adolescents 
CD4 Cell Categories Clinical Categories 
Abbreviations: PGL = persistent generalized lymphadenopathy 
 A 
Asymptomatic, Acute 
HIV, or PGL 
B* 
Symptomatic 




        (1) ≥500 cells/µL A1 B1 C1 
(2) 200-499 cells/µL A2 B2 C2 
        (3) <200 cells/µL A3 B3 C3 
 * Category B Symptomatic Conditions 
Category B symptomatic conditions are defined as symptomatic conditions occurring in an HIV-  
infected  adolescent or adult that meet at least one of the following criteria: 
 They are attributed to HIV infection or indicate a defect in cell-mediated immunity. 
 They are considered to have a clinical course or management that is complicated by HIV 
infection. 
      Examples include, but are not limited to, the following: 
 Bacillary angiomatosis 
 Oropharyngeal candidiasis (thrush) 
 Vulvovaginal candidiasis, persistent or resistant 
 Pelvic inflammatory disease (PID) 
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 Cervical dysplasia (moderate or severe)/cervical carcinoma in situ 
 Hairy leukoplakia, oral 
 Herpes zoster (shingles), involving two or more episodes or at least one dermatome 
 Idiopathic thrombocytopenic purpura 
 Constitutional symptoms, such as fever (>38.5ºC) or diarrhoea lasting >1 month 
 Peripheral neuropathy 
          # Category C AIDS-Indicator Conditions 
 Bacterial pneumonia, recurrent (two or more episodes in 12 months) 
 Candidiasis of the bronchi, trachea, or lungs 
 Candidiasis, oesophageal 
 Cervical carcinoma, invasive, confirmed by biopsy 
 Coccidioidomycosis, disseminated or extrapulmonary 
 Cryptococcosis, extrapulmonary 
 Cryptosporidiosis, chronic intestinal (>1 month in duration) 
 Cytomegalovirus disease (other than liver, spleen, or nodes) 
 Encephalopathy, HIV-related 
 Herpes simplex: chronic ulcers (>1 month in duration), or bronchitis, pneumonitis, or 
oesophagitis 
 Histoplasmosis, disseminated or extrapulmonary 
 Isosporiasis, chronic intestinal (>1-month duration) 
 Kaposi sarcoma 
 Lymphoma, Burkitt, immunoblastic, or primary central nervous system 
 Mycobacterium avium complex (MAC) or Mycobacterium kansasii, disseminated or 
extrapulmonary 
 Mycobacterium tuberculosis, pulmonary or extrapulmonary 
 Mycobacterium, other species or unidentified species, disseminated or extrapulmonary 
 Pneumocystis jiroveci (formerly carinii) pneumonia (PCP) 
 Progressive multifocal leukoencephalopathy (PML) 
 Salmonella septicaemia, recurrent (non-typhoid) 
 Toxoplasmosis of brain 
 Wasting syndrome caused by HIV (involuntary weight loss >10% of baseline body weight) 
associated with either chronic diarrhoea (two or more loose stools per day for ≥1 month) or 
chronic weakness and documented fever for ≥1 month 
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The Patients' Rights Charter  
For many decades the vast majority of the South African population has experienced either a denial or violation 
of fundamental human rights, including rights to health care services. To ensure the realisation of the right of 
access to health care services as guaranteed in the Constitution of the Republic of South Africa (Act No 108 of 
1996), the Department of Health is committed to upholding, promoting and protecting this right and therefore 
proclaims this PATIENTS' RIGHTS CHARTER as a common standard for achieving the realisation of this 
right.  
This Charter is subject to the provisions of any law operating within the Republic of South Africa and to the 
financial means of the country. 
A healthy and safe environment 
Everyone has the right to a healthy and safe environment that will ensure 
their physical and mental health or well-being, including adequate water 
supply, sanitation and waste disposal as well as protection from all forms of 





Participation in decision-making 
Every citizen has the right to participate in the development of health 
policies and everyone has the right to participate in decision-making on 
matters affecting one’s health 
 
Access to healthcare 
Everyone has the right of access to health care services that include: 
i. receiving timely emergency care at any health care facility that is 
open regardless of one's ability to pay;  
ii. treatment and rehabilitation that must be made known to the 
patient to enable the patient to understand such treatment or 




iii. provision for special needs in the case of newborn infants, children, pregnant women, the aged, disabled 
persons, patients in pain, person living with HIV or AIDS patients;  
iv. counselling without discrimination, coercion or violence on matters such as reproductive health, cancer 
or HIV/AIDS;  
v. palliative care that is affordable and effective in cases of incurable or terminal illness;  
vi. a positive disposition displayed by health care providers that demonstrate courtesy, human dignity, 
patience, empathy and tolerance; and  
vii. health information that includes the availability of health services and how best to use such services and 





Knowledge of one’s health insurance/medical aid scheme 
A member of a health insurance or medical aid scheme is entitled to 
information about that insurance or medical aid scheme and to challenge, 
where necessary, the decisions of such health insurance or medical aid 
scheme relating to the member. 
 
Choice of health services 
Everyone has the right to choose a particular health care provider for 
services or a particular health facility for treatment provided that such 
choice shall not be contrary to the ethical standards applicable to such 
health care providers or facilities, and the choice of facilities in line with 






Be treated by a named health care provider 
Everyone has the right to know the person that is providing health care and therefore 
must be attended to by clearly identified health care providers. 
 
Confidentiality and privacy 
Information concerning one’s health, including information concerning 
treatment may only be disclosed with informed consent, except when 





Everyone has the right to be given full and accurate information about the 
nature of one’s illnesses, diagnostic procedures, the proposed treatment 
and the costs involved, for one to make a decision that affects anyone of 
these elements.  
  
 
Refusal of treatment 
A person may refuse treatment and such refusal shall be verbal or in writing 






Be referred for a second opinion 
Everyone has the right to be referred for a second opinion on request to a 
health provider of one’s choice. 
 
Continuity of care 
No one shall be abandoned by a health care professional worker or a health 




Complain about health services 
Everyone has the right to complain about health care services and to have such 
complaints investigated and to receive a full response on such investigation. 
Responsibilities of the Patient 
Every patient or client has the following responsibilities: 
• to advise the health care providers on his or her wishes with regard to his or her death.  
• to comply with the prescribed treatment or rehabilitation procedures.  
• to enquire about the related costs of treatment and/or rehabilitation and to arrange for payment.  
• to take care of health records in his or her possession.  
• to take care of his or her health.  
• to care for and protect the environment.  
• to respect the rights of other patients and health providers.  
• to utilise the health care system properly and not abuse it.  
• to know his or her local health services and what they offer.  
• to provide health care providers with the relevant and accurate information for diagnostic, treatment, 
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I, Michaela Helene Naicker, student no. 981084140, am a Masters student undertaking research 
University of KwaZulu-Natal.   . 
 
The main objective of the study is to explore the factors that facilitate adherence to HIV antiretroviral 
therapy.  The specific objectives are to gather information on the following factors that facilitate HIV 
medication adherence: 
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• Health care team and system related factors 
• Condition related factors 
• Therapy related factors 
• ‘Patient’ /Person related factors 
 
This study will be supervised by Professor Vishanthie Sewpaul of the School of Social Work and 
Community Development at the University of Kwazulu-Natal. 
 
Your participation in this research is completely voluntary and you may withdraw from this study at 
any time if you so wish. 
 
I, ………………………………………………… acknowledge that I have been informed of the 
objectives of the study. I acknowledge that all information regarding the study namely risks, benefits, 
confidentiality and participation has been explained to me.  I acknowledge that all my questions 
regarding the study, was clearly explained to me.  I understand that any information provided in the 




……………………………        …………………………………… 





……………………………         …………………………………..  
SIGNATURE OF RESEARCHER        DATE 
 
……………………………………                                 ………………………………….. 








UNIVERSITY OF KWAZULU-NATAL 
            
                                         ETHICAL CLEARANCE APPLICATION FORM                2009 
                                                 (HUMAN AND SOCIAL SCIENCES) 
 
PLEASE NOTE THAT THE FORM MUST BE COMPLETED IN TYPED SCRIPT. 




SECTION 1:  PERSONAL DETAILS  
 
1.1 Full Name & Surname of Applicant     Michaela Helene Naicker 
1.2 Title (Ms/ Mr/ Mrs/ Dr/ Professor etc)  Ms 
1.3 Student Number (where applicable        981084140 
 Staff Number (where applicable)        N/A 
1.4 School                                   Social Work  
1.5 Faculty               Humanities, Developmental studies and 
        Social Science  
1.6 Campus                  Howard College     
                   
1.7     Existing Qualifications     Bachelor of Arts in Social Science; 
    Post Graduate Certificate in Education; 
    Post Graduate Diploma in Clinical   
                       HIV/Aids Management 
1.8 Proposed Qualification for Project       Masters in Social Work 
 ( In the case of research of degree purposes) 
 
2. Contact Details   
 Tel. No.       031266 7738 
 Cell. No.                               0837855046 
 e-mail                                                michaela@medis.co.za 
      Postal address (in the case of students 4 Heather Road, Westville, Durban, 3630 
          and external applicants)                            South Africa   
   
              
Supervisor’s details 
NAME TEL NO.  
 
EMAIL DEPARTMENT 
/ INSTITUTION  
QUALIFICA-
TIONS 










SECTION 2:  PROJECT DESCRIPTION  
 
 
Please do not provide your full research proposal here: what is required is a short  
project description of not more than two pages that gives, under the following  
headings, a brief overview spelling out the background to the study, the key questions  
to be addressed, the participants (or subjects) and research site, including a full  
description of the sample, and the research approach/ methods   
 
2.1 Project title               
Factors that influence adherence to highly active antiretroviral therapy (HAART)  
 
2.2 Location of the study (where will the study be conducted)   
      Durban Metropolis 
 
2.3 Objectives of and need for the study 
  
     (Set out the major objectives and the theoretical approach of the research, indicating      
     briefly, why you believe the study is needed.) 
 
The main aim is to explore the factors that influence adherence to HIV antiretroviral therapy. 
The specific objectives are to gather information on the following factors that influence HIV   
medication adherence: 
 
• Social and economic factors 
• Health care team and system related factors 
• Condition related factors 
• Therapy related factors 
• ‘Patient” /Person related factors 
 
Adherence behaviour can be described as a  multidimensional phenomenon influenced by  
the interaction of five sets of factors as described above. The ecosystems theory helps to 
provide an understanding of behaviour in  context. The Information-Motivation- 
Behaviour model provides a useful framework to explain the influence of  different 
variables on an individual’s health related behaviour.  This study seeks to explore the 
factors that influence adherence which may help health care providers and persons on 
HAART to engage in open discussion to promote near perfect adherence behaviour. 
 
2.4 Questions to be answered in the research 
 
      (Set out the critical questions which you intend to answer by undertaking this research.) 
       
• What specific influences might social and economic factors have on adherence to   
antiretroviral therapy? 




• Does the medical condition of the HIV+ person influence antiretroviral medication 
adherence? 
• Are there specific therapy related factors that might influence adherence? 
• What personal factors may influence adherence? 
 
2.5 Research approach/ methods 
 
(This section should explain how you will go about answering the critical questions which 
you have identified under 2.4 above.  Set out the approach within which you will work, and 
indicate in step-by-step point form the methods you will use in this research in order to 
answer the critical questions).  
 
This research is a qualitative descriptive study to explore the factors that influence ART 
adherence amongst persons who access health care in Durban. Eligible participants are 
persons over 21 years of age, on treatment for at least 2 years, who are willing to share stories 
with the researcher.  Participants must be able to communicate in English. 
 
The theoretical sampling technique is the technique of choice as this will provide me with the 
opportunity to obtain a deeper understanding of the factors that influence adherence.  The 
sample size will be determined by how the research questions are answered.  I anticipate 
doing at least ten interviews but will be guided by the data generated by the interviews.  
Interviews will discontinue once data saturation occurs. 
 
In-depth interviews will be conducted and participants will be identified by health care 
providers.  The interviews will be approximately one and a half hours long.  Interviews will 
be tape recorded and transcribed verbatim for thematic analysis of data. 
 
For a study that involves surveys, please append a provisional copy of the questionnaire to 
be used. The questionnaire should show how informed consent is to be achieved as well as 
indicate to respondents that they may withdraw their participation at any time, should they 
so wish. 
 
2.6 Proposed work plan 
Set out your intended plan of work for the research, indicating important target dates 
necessary to meet your proposed deadline. 
 
STEPS 
Chapter 2 – literature study ongoing – to 
complete 
Chapter 3 – Research methodology/theoretical 
framework 
Identification of Participants – explanation of 
research study, documentation 
Conducting interviews – can start in Aug is 
approval granted or else will start in September. 
Transcription immediately after interviews 
Interviews – 2 per week. Transcription 
immediately after interviews 
Transcribing 
Analyzing data 












1st and 2nd  weeks October – to complete 
3rd week October 
4th weeks October 
1st week  of November and 2nd weeks of 
128 
 
Conclusion and recommendations 
Editing & submission 
November 




SECTION   3:  ETHICAL ISSUES  
 
The UKZN Research Ethics Policy applies to all members of staff, graduate and 
undergraduate students who are involved in research on or off the campuses of University of 
KwaZulu-Natal. In addition, any person not affiliated with UKZN who wishes to conduct 
research with UKZN students and / or staff is bound by the same ethics framework. Each 
member of the University community is responsible for implementing this Policy in relation 
to scholarly work with which she or he is associated and to avoid any activity which might be 
considered to be in violation of this Policy. 
 
All students and members of staff must familiarize themselves with AND sign an undertaking 
to comply with the University’s “Code of Conduct for Research”. 
 
QUESTION 3.1           
Does your study cover research involving:  
 
YES NO 
Children  √ 
Persons who are intellectually or mentally impaired  √ 
Persons who have experienced traumatic or stressful life circumstances √  
Persons who are HIV positive √  
Persons highly dependent on medical care √  
Persons in dependent or unequal relationships  √ 
Persons in captivity  √ 








Participants’ identities will be concealed.  Only respondents willing to share their stories will 
be interviewed.  All participants will be fully informed about the nature of the study and will 
be granted the option to withdraw at any time if they so choose.  Should the interview 
generate emotional trauma the researcher will use her skills as a social worker to provide for a 
containing environment and to handle this with empathy and sensitivity.  Appropriate 
referrals will be, where necessary. 
 
QUESTION 3.2           
Will data collection involve any of the following: 
 
YES NO 
Access to confidential information without prior consent of participants 
 
 √ 
If “Yes”, indicate what measures you will take to protect the autonomy of respondents and 
(where indicated) to prevent social stigmatisation and/or secondary victimisation of 








Participants being required to commit an act which might diminish self-
respect or cause them to experience shame, embarrassment, or regret 
 
 √ 
Participants being exposed to questions which may be experienced as 
stressful or upsetting, or to procedures which may have unpleasant or 
harmful side effects 
 
 √ 
The use of stimuli, tasks or procedures which may be experienced as 
stressful, noxious, or unpleasant 
 √ 
 







QUESTION 3.3            




Questionnaire   
Survey schedule   
Interview schedule: An interview guide will be used with broad areas of 
exploration as per the main aim and objectives of the study. 
√  
Psychometric test   










 QUESTION 3.4             
Will the autonomy of participants be protected through the use of an 
informed consent form, which specifies (in language that respondents 
will understand): 
YES NO 
The nature and purpose/s of the research 
 
√  
The identity and institutional association of the researcher and 
supervisor/project leader and their contact details 
√  
The fact that participation is voluntary  
That responses will be treated in a confidential manner 
√  
Any limits on confidentiality which may apply 
 
√  
That anonymity will be ensured where appropriate (e.g. coded/ disguised 
names of participants/ respondents/ institutions) 
√  
If “Yes”, explain and justify. Explain, too, what steps you will take to minimise the 
potential stress/harm. 
 
If “Yes”, attach copy of research instrument. If data collection involves the use of a 
psychometric test or equivalent assessment instrument, you are required to provide 
evidence here that the measure is likely to provide a valid, reliable, and unbiased estimate 
of the construct being measured. If data collection involves interviews and/or focus groups, 






The fact that participants are free to withdraw from the research at any time 
without any negative or undesirable consequences to themselves 
√  
The nature and limits of any benefits participants may receive as a result of 
their participation in the research 
√  






QUESTION 3.5            
Specify what efforts been made or will be made to obtain informed permission for the 
research from appropriate authorities and gate-keepers (including caretakers or legal 
guardians in the case of minor children)? 
 
No minors are involved in this research.  Participation is voluntary.  Only persons over 21 
years who are willing and eager to share their information with me are eligible.   
 
QUESTION 3.6           
STORAGE AND DISPOSAL OF RESEARCH DATA: 
Please note that the research data should be kept for a period of at least five years in a 
secure location by arrangement with your supervisor. 
How will the research data be disposed of? Please provide specific information, eg 
shredding of documents incineration of videos, cassettes, etc.  
 
Recorded data - cassettes will be incinerated 
Verbatim transcripts will be shredded 
 
QUESTION 3.7           
In the subsequent dissemination of your research findings – in the form of the finished 
thesis, oral presentations, publication etc. – how will anonymity/ confidentiality be 
protected? 
 
Identities of participants will be concealed. 
 
QUESTION 3.8            
Is this research supported by funding that is likely to inform or impact 










Has any organization/company participating in the research or funding the project, 
imposed any conditions to the research?                                             NO              
If not, this needs to be explained and justified, also the measures to be adopted to ensure that 
the respondents fully understand the nature of the research and the consent that they are 
giving. 
 


























I have familiarised myself with the University’s Code of Conduct for Research and undertake 
to comply with it. The information supplied above is correct to the best of my knowledge. 
NB:   PLEASE ENSURE THAT THE ATTACHED CHECK SHEET IS COMPLETED  
 
………………………………………                                                                                                    
31 July 2009 




SUPERVISOR/HEAD OF SCHOOL 
 
NB: PLEASE ENSURE THAT THE APPLICANT HAS COMPLETED THE 
ATTACHED CHECK SHEET AND THAT THE FORM IS FORWARDED TO YOUR 








RECOMMENDATION OF FACULTY RESEARCH COMMITTEE/HIGHER 
DEGREES COMMITTEE 
 
The application is (please tick): 
 Approved * 
 Recommended and referred to the Human and Social Sciences Ethics Committee for 
further consideration  
 Not Approved, referred back for revision and resubmission  
 
*     Senate has delegated powers to Faculty Committee to:  
      -      Approve  Undergraduate and Honours projects  
      -      Approve Masters projects (if the required capacity exists within the faculty)  
 
NAME OF CHAIRPERSON: 
132 
 
__________________________________SIGNATURE:___________________________   
 
DATE     ……………………………………… 
 
 
RECOMMENDATION OF UNIVERSITY RESEARCH ETHICS COMMITTEE 












UNIVERSITY OF KWAZULU-NATAL 
RESEARCH OFFICE  
 
HUMAN AND SOCIAL SCIENCES ETHICAL CLEARANCE APPLICATIOM 
FORM 
 
CHECK SHEET FOR APPLICATION 
                        PLEASE TICK 
1.   Form has been fully completed and all questions have been answered   
2.   Questionnaire attached  (where applicable)  
3.   Informed consent document attached (where applicable)  
4.   Approval from relevant authorities obtained (and attached) where research  
      involves the utilization of space, data and/or facilities at other   institutions/ 
      organisations 
 
5.   Signature of Supervisor / project leader   
6.   Application forwarded to Faculty Research  Committee for recommendation and  
      transmission to the Research Office  
 
 
 
 
 
 
 
 
 
 
